
Title:
Bupropion
Text:
Substituted cathinone medication mainly for depression and smoking cessation
.mw-parser-output .hatnote{font-style:italic}.mw-parser-output div.hatnote{padding-left:1.6em;margin-bottom:0.5em}.mw-parser-output .hatnote i{font-style:normal}.mw-parser-output .hatnote+link+.hatnote{margin-top:-0.5em}Not to be confused with Buprenorphine or Buspirone.


.mw-parser-output .infobox-subbox{padding:0;border:none;margin:-3px;width:auto;min-width:100%;font-size:100%;clear:none;float:none;background-color:transparent}.mw-parser-output .infobox-3cols-child{margin:auto}.mw-parser-output .infobox .navbar{font-size:100%}body.skin-minerva .mw-parser-output .infobox-header,body.skin-minerva .mw-parser-output .infobox-subheader,body.skin-minerva .mw-parser-output .infobox-above,body.skin-minerva .mw-parser-output .infobox-title,body.skin-minerva .mw-parser-output .infobox-image,body.skin-minerva .mw-parser-output .infobox-full-data,body.skin-minerva .mw-parser-output .infobox-below{text-align:center}Bupropion1 : 1 mixture (racemate)Clinical dataPronunciation/bjuːˈproʊpiɒn/bew-PROH-pee-on Trade namesWellbutrin, Zyban, othersOther namesAmfebutamone; 3-Chloro-N-tert-butyl-β-keto-α-methylphenethylamine;3-Chloro-N-tert-butyl-β-ketoamphetamine;Bupropion hydrochloride[1]AHFS/Drugs.comMonographMedlinePlusa695033License data
EU EMA: by INN
US DailyMed: Bupropion
US FDA: Bupropion
Pregnancycategory
AU: B2[2]

Routes ofadministrationBy mouthDrug classAntidepressantsATC codeN06AX12 (WHO) Legal statusLegal status
AU: S4 (Prescription only) 
CA:  ℞-only 
UK: POM (Prescription only) 
US: ℞-only 
EU: Rx-only 
In general: ℞ (Prescription only)
Pharmacokinetic dataProtein binding84% (bupropion), 77% (hydroxybupropion metabolite), 42% (threo-hydrobupropion metabolite)[3]MetabolismLiver, intestines[5]Elimination half-life11–21 hours[4][5]ExcretionUrine (87%; 0.5% unchanged), faecal (10%)[5]Identifiers
IUPAC name
(RS)-2-(tert-Butylamino)-1-(3-chlorophenyl)propan-1-one
CAS Number34911-55-2 Y[PubChem]PubChem CID444IUPHAR/BPS7135DrugBankDB01156 YChemSpider431 YUNII01ZG3TPX31KEGGD07591 Yas HCl: D00817 YChEBICHEBI:3219 YChEMBLChEMBL894 YCompTox Dashboard (EPA)DTXSID7022706 Chemical and physical dataFormulaC13H18ClNOMolar mass239.74 g·mol−13D model (JSmol)Interactive image
SMILES
O=C(C(C)NC(C)(C)C)C1=CC=CC(Cl)=C1

InChI
InChI=1S/C13H18ClNO/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10/h5-9,15H,1-4H3 YKey:SNPPWIUOZRMYNY-UHFFFAOYSA-N Y
.mw-parser-output .nobold{font-weight:normal}  (verify)
Bupropion, sold under the brand names Wellbutrin and Zyban among others, is an atypical antidepressant primarily used to treat major depressive disorder and to support smoking cessation.[6][7] Bupropion is an effective antidepressant on its own, but it is also popular as an add-on medication in the cases of incomplete response to the first-line selective serotonin reuptake inhibitor (SSRI) antidepressant.[7][8] Bupropion has several features that distinguish it from other antidepressants: it does not usually cause sexual dysfunction;[7] it is not associated with weight gain[7] and sleepiness,[9] and it is more effective than SSRIs at improving symptoms of hypersomnia and fatigue.[10] Bupropion does, however, carry a much higher risk of seizure than many other antidepressants and extreme caution must be taken in patients with a history of seizure disorder.
Common adverse effects of bupropion with the greatest difference from placebo are dry mouth, nausea, constipation, insomnia, anxiety, tremor, and excessive sweating.[11] Raised blood pressure is notable.[12] Rare but serious side effects include seizure,[11] liver toxicity,[13] psychosis,[14] and risk of overdose.[15] Bupropion use during pregnancy may be associated with increased odds of congenital heart defects.[16]
Bupropion acts as a norepinephrine–dopamine reuptake inhibitor and a nicotinic receptor antagonist.[5] Chemically, it is an aminoketone that belongs to the class of substituted cathinones and more generally that of substituted amphetamines and substituted phenethylamines.[1][17]
Bupropion was invented by Nariman Mehta, who worked at Burroughs Wellcome, in 1969.[18] It was first approved for medical use in the United States in 1985.[19] Bupropion was originally called by the generic name amfebutamone, before being renamed in 2000.[20] In 2019, it was the 22nd most commonly prescribed medication in the United States, with more than 25 million prescriptions.[21][22] It is on the World Health Organization's List of Essential Medicines.[23]

.mw-parser-output .toclimit-2 .toclevel-1 ul,.mw-parser-output .toclimit-3 .toclevel-2 ul,.mw-parser-output .toclimit-4 .toclevel-3 ul,.mw-parser-output .toclimit-5 .toclevel-4 ul,.mw-parser-output .toclimit-6 .toclevel-5 ul,.mw-parser-output .toclimit-7 .toclevel-6 ul{display:none}Contents

1 Medical uses

1.1 Depression
1.2 Smoking cessation
1.3 Attention deficit hyperactivity disorder
1.4 Sexual dysfunction
1.5 Obesity
1.6 Other uses
1.7 Available forms


2 Contraindications
3 Side effects

3.1 Psychiatric


4 Overdose
5 Interactions
6 Pharmacology

6.1 Pharmacodynamics and mechanism of action
6.2 Pharmacokinetics


7 Chemistry

7.1 Synthesis


8 History
9 Society and culture

9.1 Recreational use
9.2 Legal status


10 References
11 External links



Medical uses[edit]
  Wellbutrin XL
Depression[edit]
A majority of controlled clinical trials support efficacy of bupropion for the treatment of depression.[24][7][25] However, the overall quality of the evidence is low,[25][7] with one meta-analysis, for example, finding a small[25] effect size of bupropion in depression and another finding a large[7] effect size. Comparative head-to-head clinical trials indicate that bupropion is similar in response rate against depression to fluoxetine, sertraline, paroxetine, and venlafaxine; meanwhile remission rate tends to favor bupropion.[7]
Over the fall and winter months, bupropion prevents development of depression in those who suffer from recurring seasonal affective disorder: 15% of participants on bupropion experienced a major depressive episode vs. 27% of those on placebo.[26] Bupropion also improves depression in bipolar disorder, with the efficacy and risk of affective switch being similar to other antidepressants.[27]
Bupropion has several features that distinguish it from other antidepressants: for instance, unlike the majority of antidepressants, it does not usually cause sexual dysfunction, and the occurrence of sexual side effects is not different from placebo.[7][28] Bupropion treatment is not associated with weight gain; on the contrary, the majority of studies observed significant weight loss in bupropion-treated participants.[7] Bupropion treatment also is not associated with the sleepiness that may be produced by other antidepressants.[9] Bupropion is more effective than selective serotonin reuptake inhibitors (SSRIs) at improving symptoms of hypersomnia and fatigue in depressed patients.[10] There appears to be a modest advantage for the SSRIs compared to bupropion in the treatment of depression with high anxiety; they are equivalent for the depression with moderate or low anxiety.[29]
The addition of bupropion to a prescribed SSRI is a common strategy when people do not respond to the SSRI,[8] and it is supported by clinical trials;[7] however, it appears to be inferior to the addition of atypical antipsychotic aripiprazole.[30]

Smoking cessation[edit]
Prescribed as an aid for smoking cessation bupropion reduces the severity of craving for tobacco and withdrawal symptoms[31][32][33] such as depressed
mood, irritability, difficulty concentrating, and increased appetite.[34] Initially, bupropion slows the weight gain that often occurs in the first weeks after quitting smoking. With time, however, this effect becomes negligible.[34]
The bupropion treatment course lasts for seven to twelve weeks, with the patient halting the use of tobacco about ten days into the course.[34][35] After the course, the effectiveness of bupropion for maintaining abstinence from smoking declines over time, from 37% of tobacco abstinence at 3 months to 20% at one year.[36] It is unclear whether extending bupropion treatment helps to prevent relapse of smoking.[37]
Overall, six months after the therapy, bupropion increases the likelihood of quitting smoking by approximately 1.6 fold as compared to placebo. In this respect, bupropion is as effective as nicotine replacement therapy but inferior to varenicline. Combining bupropion and nicotine replacement therapy does not improve the quitting rate.[38] 
In children and adolescents, the use of bupropion for smoking cessation does not appear to offer any significant benefits.[39] The evidence for its use to aid smoking cessation in pregnant women is insufficient.[40]

Attention deficit hyperactivity disorder[edit]
The treatment of attention deficit hyperactivity disorder (ADHD) is not an approved indication of bupropion, and it is not mentioned in the current (2019) guideline on the ADHD treatment from the American Academy of Pediatrics.[41] Systematic reviews of bupropion for the treatment of ADHD in both adults and children note that bupropion may be effective for ADHD but warn that this conclusion has to be interpreted with caution, because clinical trials were of low quality due to small sizes and risk of bias.[42][43][44][45] Similarly to atomoxetine, bupropion has a delayed onset of action for ADHD, and several weeks of treatment are required for therapeutic effects.[42][46] This is in contrast to stimulants, such as amphetamine and methylphenidate, which have an immediate onset of effect in the condition.[46]

Sexual dysfunction[edit]
Bupropion is less likely than other antidepressants to cause sexual dysfunction.[47] A range of studies indicate that bupropion not only produces fewer sexual side effects than other antidepressants but can actually help to alleviate sexual dysfunction[48] including sexual dysfunction induced by SSRI antidepressants.[49] There have also been small studies suggesting that bupropion or a bupropion/trazodone combination may improve some measures of sexual function in women who have hypoactive sexual desire disorder (HSDD) and are not depressed.[50] According to an expert consensus recommendation from the International Society for the Study of Women's Sexual Health, bupropion can be considered as an off-label treatment for HSDD despite limited safety and efficacy data.[51]

Obesity[edit]
Bupropion, when used for treating obesity over a period of 6 to 12 months, results in an average weight loss of 2.7 kg (5.9 lbs) over placebo.[52] This is not much different from the weight loss produced by several other weight-loss medications such as sibutramine or orlistat.[52] The combination drug naltrexone/bupropion has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of obesity.[53][54]

Other uses[edit]
Bupropion is not effective in the treatment of cocaine dependence,[55] but it is showing promise in reducing drug use in light methamphetamine users.[56] Based on studies indicating that bupropion lowers the level of the inflammatory mediator TNF-alpha, there have been suggestions that it might be useful in treating inflammatory bowel disease, psoriasis, and other autoimmune conditions, but very little clinical evidence is available.[57][58][59] Bupropion is not effective in treating chronic low back pain.[60]

Available forms[edit]
Bupropion is available as an oral tablet in a number of different formulations.[61] It is formulated mostly as the hydrochloride salt but also to a lesser extent as the hydrobromide salt.[61] The available forms of bupropion hydrochloride include IR (instant-release) tablets (50, 75, 100 mg), SR (sustained-release) tablets (50, 100, 150, 200 mg), and XL (extended-release) tablets (150, 300, 450 mg).[61] The only marketed form of bupropion hydrobromide is Aplenzin, an extended-release oral tablet (174, 348, 522 mg).[61] In addition to single-drug formulations, bupropion is formulated in combinations including naltrexone/bupropion (Contrave; 8 mg/90 mg extended-release tablets)[61] and the pending-approval bupropion/dextromethorphan (AXS-05; 105 mg/45 mg tablets).[62][63]

Contraindications[edit]
The drug label advises that bupropion should not be prescribed to individuals with epilepsy or other conditions that lower the seizure threshold, such as anorexia nervosa, bulimia nervosa, benzodiazepine or alcohol withdrawal. It should be avoided in individuals who are taking monoamine oxidase inhibitors (MAOIs). When switching from MAOIs to bupropion, it is important to include a washout period of about two weeks between the medications.[64] The label recommends that caution should be exercised when treating people with liver damage, severe kidney disease, and severe hypertension, and in children, adolescents and young adults due to the increased risk of suicidal ideation.[64]

Side effects[edit]
See also: List of side effects of bupropion
The common adverse effects of bupropion with the greatest difference from placebo are dry mouth, nausea, constipation, insomnia, anxiety, tremor, and excessive sweating.[11] Bupropion has the highest incidence of insomnia of all second-generation antidepressants, apart from desvenlafaxine.[65] It is also associated with about 20% increased risk of headache.[66]
Bupropion raises blood pressure in some people. One study showed an average rise of 6 mm Hg in sysolic blood pressure in 10% of patients.[12] The prescribing information notes that hypertension, sometimes severe, is observed in some people taking bupropion, both with and without pre-existing hypertension.[11] Safety of bupropion in people with cardiovascular conditions and its general cardiovascular safety profile remain unclear due to the lack of data.[67][68]
Seizure is a rare but serious adverse effect of bupropion. It is strongly dose-dependent: for the immediate release preparation, the seizure incidence is 0.4% at the dose 300–450 mg per day; the incidence climbs almost ten-fold for the higher than recommended dose of 600 mg.[11] For comparison, the incidence of unprovoked seizure in the general population is 0.07 to 0.09%, and the risk of seizure for a variety of other antidepressants is generally between 0 and 0.5% at the recommended doses.[69]
Cases of liver toxicity leading to death or liver transplantation have been reported for bupropion. It is considered to be one of several antidepressants with greater risk of hepatotoxicity.[13]
The prescribing information warns about bupropion triggering an angle-closure glaucoma attack.[64] On the other hand, bupropion may decrease the risk of development of open angle glaucoma.[70]
Bupropion use by mothers in the first trimester of pregnancy is associated with 23% increase of the odds in congenital heart defects in their children.[16]
Bupropion has rarely been associated with instances of Stevens–Johnson syndrome.[71][72]

Psychiatric[edit]
The FDA requires all antidepressants, including bupropion, to carry a boxed warning stating that antidepressants may increase the risk of suicide in persons younger than 25. This warning is based on a statistical analysis conducted by the FDA which found a 2-fold increase in suicidal thought and behavior in children and adolescents, and 1.5-fold increase in the 18–24 age group.[73] For this analysis the FDA combined the results of 295 trials of 11 antidepressants in order to obtain statistically significant results. Considered in isolation, bupropion was not statistically different from placebo.[73]
Bupropion prescribed for smoking cessation results in 25% increase of the risk of psychiatric side effects, in particular, anxiety (about 40% increase) and insomnia (about 80% increase). The evidence is insufficient to determine whether bupropion is associated with suicides or suicidal behavior.[74] 
In rare cases, bupropion-induced psychosis may develop. It is associated with higher doses of bupropion; many cases described are at higher than recommended doses. Concurrent antipsychotic medication appears to be protective.[14] In most cases the psychotic symptoms are eliminated by reducing the dose, ceasing treatment or adding antipsychotic medication.[64][14]
Although studies are lacking, a handful of case reports suggest that abrupt discontinuation of bupropion may cause antidepressant discontinuation syndrome.[75]

Overdose[edit]
Bupropion is considered moderately dangerous in overdose.[76][77] According to an analysis of US National Poison Data System, adjusted for the number of prescriptions, bupropion and venlafaxine are the two new generation antidepressants (that is excluding tricyclic antidepressants) that result in the highest mortality and morbidity.[15] For significant overdoses, seizures have been reported in about a third of all cases; other serious effects include hallucinations, loss of consciousness, and abnormal heart rhythms. When bupropion was one of several kinds of pills taken in an overdose, fever, muscle rigidity, muscle damage, hypertension or hypotension, stupor, coma, and respiratory failure have been reported. While most people recover, some people have died, having suffered multiple uncontrolled seizures and heart attacks.[64]

Interactions[edit]
Since bupropion is metabolized to hydroxybupropion by the enzyme CYP2B6, drug interactions with CYP2B6 inhibitors are possible: this includes such medications as paroxetine, sertraline, norfluoxetine (active metabolite of fluoxetine), diazepam, clopidogrel, and orphenadrine. The expected result is the increase of bupropion and decrease of hydroxybupropion blood concentration. The reverse effect (decrease of bupropion and increase of hydroxybupropion) can be expected with CYP2B6 inducers such as carbamazepine, clotrimazole, rifampicin, ritonavir, St John's wort, and phenobarbital.[78] Indeed, carbamazepine decreases exposure to bupropion by 90% and increases exposure to hydroxybupropion by 94%.[79] Ritonavir, lopinavir/ritonavir, and efavirenz have been shown to decrease levels of bupropion and/or its metabolites.[80] Ticlopidine and clopidogrel, both potent CYP2B6 inhibitors, have been found to considerably increase bupropion levels as well as decrease levels of its metabolite hydroxybupropion.[80]
Bupropion and its metabolites are inhibitors of CYP2D6, with hydroxybupropion responsible for most of the inhibition. Additionally, bupropion and its metabolites may decrease expression of CYP2D6 in the liver. The end effect is a significant slowing of the clearance of other drugs metabolized by this enzyme.[5] For instance, bupropion has been found to increase area-under-the-curve of desipramine, a CYP2D6 substrate, by 5-fold.[80] Bupropion has also been found to increase levels of atomoxetine by 5.1-fold, while decreasing the exposure to its main metabolite by 1.5-fold.[81] As another example, the ratio of dextromethorphan (a drug that is mainly metabolized by CYP2D6) to its major metabolite dextrorphan increased approximately 35-fold when it was administered to people being treated with 300 mg/day bupropion.[78] When people on bupropion are given MDMA, about 30% increase of exposure to both drugs is observed, with enhanced mood but decreased heart rate effects of MDMA.[82][83] Interactions with other CYP2D6 substrates, such as metoprolol, imipramine, nortriptyline,[83] venlafaxine,[78] and nebivolol[5] have also been reported. However, in a notable exception, bupropion does not seem to affect the concentrations of CYP2D6 substrates fluoxetine and paroxetine.[78][84]
Bupropion lowers the seizure threshold, and therefore can potentially interact with other medications that also lower it, such as antipsychotics, tricyclic antidepressants, theophylline, and systemic corticosteroids.[64] The prescribing information recommends minimizing the use of alcohol, since in rare cases bupropion reduces alcohol tolerance.[64]
Caution should be observed when combining bupropion with a monoamine oxidase inhibitor (MAOI), as it may result in hypertensive crisis.[85]

Pharmacology[edit]

Pharmacology of bupropion and its metabolites.


 

Bupropion

R,R-Hydroxybupropion

S,S-Hydroxybupropion

Threo-hydrobupropion

Erythro-hydrobupropion


Exposure and half-life


AUC relativeto bupropion[86][87]

1

23.8

0.6

11.2

2.5


Half-life[4]

11 h

19 h

15 h

31 h

22 h


Inhibition IC50 (μM) in human cells, unless noted otherwise


DAT, uptake[88]

0.66

inactive

0.63

47 (rat)[89]

no data


NET, uptake[88]

1.85

9.9

0.24

16 (rat)[89]

no data


SERT, uptake[88]

inactive

inactive

inactive

67 (rat)[89]

no data


α3β4 nicotinic[88]

1.8

6.5

11

14 (rat)[90]

no data


α4β2 nicotinic[91]

12

31

3.3

no data

no data


α1β1γδ nicotinic[91]

7.9

7.6

28

no data

no data


Pharmacodynamics and mechanism of action[edit]
The mechanism of action of bupropion is unclear but believed to be related to the fact that bupropion is a norepinephrine–dopamine reuptake inhibitor (NDRI) and antagonist of several nicotinic acetylcholine receptors.[5] It is uncertain if it is a norepinephrine–dopamine releasing agent.[5] Pharmacological actions of bupropion, to a significant degree, are due to its active metabolites hydroxybupropion, threo-hydrobupropion, and erythro-hydrobupropion that are present in the blood plasma at comparable or higher levels.[5] Overall action of these metabolites, and particularly one enantiomer S,S-hydroxybupropion, is also characterized by inhibition of norepinephrine and dopamine reuptake and nicotinic antagonism (see the chart on the right).[5] Bupropion has no meaningful direct activity at a variety of receptors, including α- and β-adrenergic, dopamine, serotonin, histamine, and muscarinic acetylcholine receptors.[9]
The occupancy of dopamine transporter (DAT) by bupropion (300 mg/day) and its metabolites in the human brain as measured by several positron emission tomography (PET) studies is approximately 20%, with a mean occupancy range of about 14 to 26%.[92][93][42] For comparison, the NDRI methylphenidate at therapeutic doses is thought to occupy greater than 50% of DAT sites.[42] In accordance with its low DAT occupancy, no measurable dopamine release in the human brain was detected with bupropion (150 mg/day) in a PET study.[92][93] These findings raise questions about the role of dopamine reuptake inhibition in the pharmacology of bupropion, and suggest that other actions may be responsible for its therapeutic effects.[92][42][93] More research is needed in this area.[94] No data are available on occupancy of the norepinephrine transporter (NET) by bupropion and its metabolites.[92] However, due to the increased exposure of hydroxybupropion over bupropion itself, which has higher affinity to NET than DAT (R,R- has no DAT affinity at all, and S,S- has ~3x higher affinity to NET over DAT), bupropion's overall pharmacological profile in humans may end up making it effectively more of an NRI than a DRI.[88]

Pharmacokinetics[edit]
  Principal pathways of bupropion metabolism.
After oral administration, bupropion is rapidly and completely absorbed reaching the peak blood plasma concentration after 1.5 hours (tmax). Sustained release (SR) and extended release (XL) formulations have been designed to slow down absorption resulting in tmax of 3 hours and 5 hours, respectively.[78] Absolute bioavailability of bupropion is unknown but is presumed to be low, at 5–20%, due to the first-pass metabolism. As for the relative biovailability of the formulations, XL formulation has lower bioavailability (68%) compared to SR formulation and immediate release bupropion.[5] 
Bupropion is metabolized in the body by a variety of pathways. The oxidative pathways are by cytochrome P450 isoenzymes CYP2B6 leading to R,R- and S,S-hydroxybupropion and, to a lesser degree, CYP2C19 leading to 4'-hydroxybupropion. The reductive pathways are by 11β-hydroxysteroid dehydrogenase type 1 in the liver and AKR7A2/AKR7A3 in the intestine leading to threo-hydrobupropion and by yet unknown enzyme leading to erythro-hydrobupropion.[5] (see Scheme on the right)
The metabolism of bupropion is highly variable: the effective doses of bupropion received by persons who ingest the same amount of the drug may differ by as much as 5.5 times (with a half-life of 12–30 hours), while the effective doses of hydroxybupropion may differ by as much as 7.5 times (with a half-life of 15–25 hours).[64][95][96] Based on this, some researchers have advocated monitoring of the blood level of bupropion and hydroxybupropion.[97]

Chemistry[edit]
Bupropion is an aminoketone that belongs to the class of substituted cathinones and the more general class of substituted phenethylamines.[1][17] The clinically used bupropion is racemic, that is a mixture of two enantiomers: S-bupropion and R-bupropion. Although the optical isomers on bupropion can be separated, they rapidly racemize under physiological conditions.[5][98]
There have been reported cases of false-positive urine amphetamine tests in persons taking bupropion.[99][100][101]

Synthesis[edit]
It is synthesized in two chemical steps starting from 3'-chloro-propiophenone. The alpha position adjacent to the ketone is first brominated followed by nucleophilic displacement of the resulting alpha-bromoketone with t-butylamine and treated with hydrochloric acid to give bupropion as the hydrochloride salt in 75–85% overall yield.[18][102]







 
 

3'-chloro-propiophenone
3'-chloro-2-bromopropiophenone
bupropion hydrochloride


This diagram shows the synthesis of bupropion via 3'-chloro-propiophenone.



History[edit]
  Comparison of steady-state plasma bupropion levels with bupropion IR 100 mg t.i.d. (3x/day), bupropion SR 150 mg b.i.d. (2x/day), and bupropion XL 300 mg q.d. (1x/day).[103][78]
Bupropion was invented by Nariman Mehta of Burroughs Wellcome (now GlaxoSmithKline) in 1969, and the US patent for it was granted in 1974.[18] It was approved by the U.S. Food and Drug Administration (FDA) as an antidepressant on 30 December 1985, and marketed under the name Wellbutrin.[19][104] However, a significant incidence of seizures at the originally recommended dosage (400–600 mg/day) caused the withdrawal of the drug in 1986. Subsequently, the risk of seizures was found to be highly dose-dependent, and bupropion was re-introduced to the market in 1989 with a lower maximum recommended daily dose of 450 mg/day.[105]
In 1996, the FDA approved a sustained-release formulation of alcohol-resistant bupropion called Wellbutrin SR, intended to be taken twice a day (as compared with three times a day for immediate-release Wellbutrin).[106] In 2003, the FDA approved another sustained-release formulation called Wellbutrin XL, intended for once-daily dosing.[107] Wellbutrin SR and XL are available in generic form in the United States and Canada. In 1997, bupropion was approved by the FDA for use as a smoking cessation aid under the name Zyban.[108][106] In 2006, Wellbutrin XL was similarly approved as a treatment for seasonal affective disorder.[109][110]
In France, marketing authorization was granted for Zyban on 3 August 2001, with a maximum daily dose of 300 mg; only sustained-release bupropion is available, and only as a smoking cessation aid.[111]
On 11 October 2007, two providers of consumer information on nutritional products and supplements, ConsumerLab.com and The People's Pharmacy, released the results of comparative tests of different brands of bupropion.[112] The People's Pharmacy received multiple reports of increased side effects and decreased efficacy of generic bupropion, which prompted it to ask ConsumerLab.com to test the products in question. The tests showed that "one of a few generic versions of Wellbutrin XL 300 mg, sold as Budeprion XL 300 mg, didn't perform the same as the brand-name pill in the lab."[113] The FDA investigated these complaints and concluded that Budeprion XL is equivalent to Wellbutrin XL in regard to bioavailability of bupropion and its main active metabolite hydroxybupropion. The FDA also said that coincidental natural mood variation is the most likely explanation for the apparent worsening of depression after the switch from Wellbutrin XL to Budeprion XL.[114] On 3 October 2012, however, the FDA reversed this opinion, announcing that "Budeprion XL 300 mg fails to demonstrate therapeutic equivalence to Wellbutrin XL 300 mg."[115] The FDA did not test the bioequivalence of any of the other generic versions of Wellbutrin XL 300 mg, but requested that the four manufacturers submit data on this question to the FDA by March 2013.[115] As of October 2013[update] the FDA has made determinations on the formulations from some manufacturers not being bioequivalent.[115]
In April 2008, the FDA approved a formulation of bupropion as a hydrobromide salt instead of a hydrochloride salt, to be sold under the name Aplenzin by Sanofi-Aventis.[116][117][118]
In 2009, the FDA issued a health advisory warning that the prescription of bupropion for smoking cessation has been associated with reports about unusual behavior changes, agitation and hostility. Some people, according to the advisory, have become depressed or have had their depression worsen, have had thoughts about suicide or dying, or have attempted suicide.[119] This advisory was based on a review of anti-smoking products that identified 75 reports of "suicidal adverse events" for bupropion over ten years.[120] Based on the results of follow-up trials this warning was removed in 2016.[121]
In 2012, the U.S. Justice Department announced that GlaxoSmithKline had agreed to plead guilty and pay a $3-billion fine, in part for promoting the unapproved use of Wellbutrin for weight loss and sexual dysfunction.[122]
In 2017, the European Medicines Agency recommended suspending a number of nationally approved medicines due to misrepresentation of bioequivalence study data by Micro Therapeutic Research Labs in India.[123] The products recommended for suspension included several 300 mg modified-release bupropion tablets.[124]

Society and culture[edit]
Recreational use[edit]
While bupropion demonstrates some potential for misuse, this potential is less than of other commonly used stimulants, being limited by features of its pharmacology.[125] Bupropion misuse is uncommon.[125] There have been a number of anecdotal and case-study reports of bupropion abuse, but the bulk of evidence indicates that the subjective effects of bupropion when taken orally are markedly different from those of addictive stimulants such as cocaine or amphetamine.[126] However, bupropion, by non-conventional routes of administration like injection or insufflation has been reported to be misused in the United States and Canada, notably in prisons.[127][128][129][130]

Legal status[edit]
In Russia bupropion is banned as a narcotic drug, yet not per se but rather as a derivative of methcathinone.[131]
In Australia and the UK, smoking cessation is the only licensed use of bupropion.[132][133]

References[edit]
.mw-parser-output .reflist{font-size:90%;margin-bottom:0.5em;list-style-type:decimal}.mw-parser-output .reflist .references{font-size:100%;margin-bottom:0;list-style-type:inherit}.mw-parser-output .reflist-columns-2{column-width:30em}.mw-parser-output .reflist-columns-3{column-width:25em}.mw-parser-output .reflist-columns{margin-top:0.3em}.mw-parser-output .reflist-columns ol{margin-top:0}.mw-parser-output .reflist-columns li{page-break-inside:avoid;break-inside:avoid-column}.mw-parser-output .reflist-upper-alpha{list-style-type:upper-alpha}.mw-parser-output .reflist-upper-roman{list-style-type:upper-roman}.mw-parser-output .reflist-lower-alpha{list-style-type:lower-alpha}.mw-parser-output .reflist-lower-greek{list-style-type:lower-greek}.mw-parser-output .reflist-lower-roman{list-style-type:lower-roman}

^ a b c .mw-parser-output cite.citation{font-style:inherit;word-wrap:break-word}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .cs1-ws-icon a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg")right 0.1em center/12px no-repeat}.mw-parser-output .cs1-code{color:inherit;background:inherit;border:none;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;color:#d33}.mw-parser-output .cs1-visible-error{color:#d33}.mw-parser-output .cs1-maint{display:none;color:#3a3;margin-left:0.3em}.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}"Compound Summary". Bupropion. PubChem Compound. United States National Library of Medicine – National Center for Biotechnology Information. 28 July 2018. Retrieved 29 July 2018.

^ "Bupropion Use During Pregnancy". Drugs.com. Retrieved 24 December 2018.

^ "Zyban 150 mg prolonged release film-coated tablets – Summary of Product Characteristics (SPC)". electronic Medicines Compendium. GlaxoSmithKline UK. 1 August 2013. Retrieved 22 October 2013.

^ a b Masters AR, Gufford BT, Lu JB, Metzger IF, Jones DR, Desta Z (August 2016). "Chiral Plasma Pharmacokinetics and Urinary Excretion of Bupropion and Metabolites in Healthy Volunteers". The Journal of Pharmacology and Experimental Therapeutics. 358 (2): 230–238. doi:10.1124/jpet.116.232876. PMC 4959100. PMID 27255113.

^ a b c d e f g h i j k l m Costa R, Oliveira NG, Dinis-Oliveira RJ (August 2019). "Pharmacokinetic and pharmacodynamic of bupropion: integrative overview of relevant clinical and forensic aspects". Drug Metabolism Reviews. 51 (3): 293–313. doi:10.1080/03602532.2019.1620763. PMID 31124380. S2CID 163167323.

^ Sweetman S (2011). Martindale: The Complete Drug Reference (37th ed.). p. 402. ISBN 9780853699828.

^ a b c d e f g h i j k Patel K, Allen S, Haque MN, Angelescu I, Baumeister D, Tracy DK (April 2016). "Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant". Therapeutic Advances in Psychopharmacology. 6 (2): 99–144. doi:10.1177/2045125316629071. PMC 4837968. PMID 27141292.

^ a b Arandjelovic K, Eyre HA, Lavretsky H (October 2016). "Clinicians' Views on Treatment-Resistant Depression: 2016 Survey Reports". The American Journal of Geriatric Psychiatry. 24 (10): 913–917. doi:10.1016/j.jagp.2016.05.010. PMC 5540329. PMID 27591914.

^ a b c Dhillon S, Yang LP, Curran MP (2008). "Bupropion: a review of its use in the management of major depressive disorder". Drugs. 68 (5): 653–689. doi:10.2165/00003495-200868050-00011. PMID 18370448.

^ a b Baldwin DS, Papakostas GI (2006). "Symptoms of fatigue and sleepiness in major depressive disorder". The Journal of Clinical Psychiatry. 67 (Suppl 6): 9–15. PMID 16848671.

^ a b c d e "Wellbutrin XL® Prescribing Information" (PDF). GlaxoSmithKline. June 2006. Archived from the original (PDF) on 17 July 2011.

^ a b Wilens TE, Hammerness PG, Biederman J, Kwon A, Spencer TJ, Clark S,  et al. (February 2005). "Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder". The Journal of Clinical Psychiatry. 66 (2): 253–259. doi:10.4088/jcp.v66n0215. PMID 15705013.

^ a b Voican CS, Corruble E, Naveau S, Perlemuter G (April 2014). "Antidepressant-induced liver injury: a review for clinicians". The American Journal of Psychiatry. 171 (4): 404–415. doi:10.1176/appi.ajp.2013.13050709. PMID 24362450.

^ a b c Kumar S, Kodela S, Detweiler JG, Kim KY, Detweiler MB (November–December 2011). "Bupropion-induced psychosis: folklore or a fact? A systematic review of the literature". General Hospital Psychiatry. 33 (6): 612–617. doi:10.1016/j.genhosppsych.2011.07.001. PMID 21872337.

^ a b Nelson JC, Spyker DA (May 2017). "Morbidity and Mortality Associated With Medications Used in the Treatment of Depression: An Analysis of Cases Reported to U.S. Poison Control Centers, 2000-2014". The American Journal of Psychiatry. 174 (5): 438–450. doi:10.1176/appi.ajp.2016.16050523. PMID 28135844.

^ a b De Vries C, Gadzhanova S, Sykes MJ, Ward M, Roughead E (March 2021). "A Systematic Review and Meta-Analysis Considering the Risk for Congenital Heart Defects of Antidepressant Classes and Individual Antidepressants". Drug Safety. 44 (3): 291–312. doi:10.1007/s40264-020-01027-x. PMID 33354752. S2CID 229357583.

^ a b Dye LR, Murphy C, Calello DP, Levine MD, Skolnik A (2017). Case Studies in Medical Toxicology: From the American College of Medical Toxicology. Springer. p. 85. ISBN 9783319564494.

^ a b c Mehta NB (25 June 1974). "United States Patent 3,819,706: Meta-chloro substituted α-butylamino-propiophenones". USPTO. Retrieved 2 June 2008.

^ a b "Wellbutrin approval package" (PDF). U.S. Food and Drug Administration (FDA). 30 December 1985. Retrieved 5 May 2020.

^ World Health Organization (2000). "International nonproprietary names for pharmaceutical substances (INN) : proposed international nonproprietary names : list 83". WHO Drug Information. 14 (2). hdl:10665/58135.

^ "The Top 300 of 2019". ClinCalc. Retrieved 16 October 2021.

^ "Bupropion - Drug Usage Statistics". ClinCalc. Retrieved 16 October 2021.

^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.

^ Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R,  et al. (February 2009). "Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis". Lancet. 373 (9665): 746–758. doi:10.1016/S0140-6736(09)60046-5. PMID 19185342. S2CID 35858125.

^ a b c Monden R, Roest AM, van Ravenzwaaij D, Wagenmakers EJ, Morey R, Wardenaar KJ, de Jonge P (August 2018). "The comparative evidence basis for the efficacy of second-generation antidepressants in the treatment of depression in the US: A Bayesian meta-analysis of Food and Drug Administration reviews" (PDF). Journal of Affective Disorders. 235: 393–398. doi:10.1016/j.jad.2018.04.040. hdl:11370/842b1441-d0f3-4797-b95b-3a6a72262150. PMID 29677603. S2CID 5011570.

^ Gartlehner G, Nussbaumer-Streit B, Gaynes BN, Forneris CA, Morgan LC, Greenblatt A,  et al. (March 2019). "Second-generation antidepressants for preventing seasonal affective disorder in adults". The Cochrane Database of Systematic Reviews. 3: CD011268. doi:10.1002/14651858.CD011268.pub3. PMC 6422318. PMID 30883669.

^ Li DJ, Tseng PT, Chen YW, Wu CK, Lin PY (March 2016). "Significant Treatment Effect of Bupropion in Patients With Bipolar Disorder but Similar Phase-Shifting Rate as Other Antidepressants: A Meta-Analysis Following the PRISMA Guidelines". Medicine. 95 (13): e3165. doi:10.1097/MD.0000000000003165. PMC 4998539. PMID 27043678.

^ Clayton AH (2003). "Antidepressant-Associated Sexual Dysfunction: A Potentially Avoidable Therapeutic Challenge". Primary Psychiatry. 10 (1): 55–61. Archived from the original on 4 June 2020. Retrieved 21 March 2013.

^ Papakostas GI, Stahl SM, Krishen A, Seifert CA, Tucker VL, Goodale EP, Fava M (August 2008). "Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies". The Journal of Clinical Psychiatry. 69 (8): 1287–1292. doi:10.4088/JCP.v69n0812. PMID 18605812. S2CID 25267685.

^ Ruberto VL, Jha MK, Murrough JW (June 2020). "Pharmacological Treatments for Patients with Treatment-Resistant Depression". Pharmaceuticals. 13 (6): 116. doi:10.3390/ph13060116. PMC 7345023. PMID 32512768.

^ Wilkes S (2008). "The use of bupropion SR in cigarette smoking cessation". International Journal of Chronic Obstructive Pulmonary Disease. 3 (1): 45–53. doi:10.2147/copd.s1121. PMC 2528204. PMID 18488428.

^ Howes S, Hartmann-Boyce J, Livingstone-Banks J, Hong B, Lindson N (April 2020). "Antidepressants for smoking cessation". The Cochrane Database of Systematic Reviews. 4: CD000031. doi:10.1002/14651858.CD000031.pub5. PMC 7175455. PMID 32319681.

^ Wu P, Wilson K, Dimoulas P, Mills EJ (December 2006). "Effectiveness of smoking cessation therapies: a systematic review and meta-analysis". BMC Public Health. 6: 300. doi:10.1186/1471-2458-6-300. PMC 1764891. PMID 17156479.

^ a b c Mooney ME, Sofuoglu M (July 2006). "Bupropion for the treatment of nicotine withdrawal and craving". Expert Review of Neurotherapeutics. 6 (7): 965–981. doi:10.1586/14737175.6.7.965. PMID 16831112. S2CID 19195413.

^ "DailyMed - BUPROPION HYDROCHLORIDE SR - bupropion hydrochloride tablet, film coated, extended release".

^ Rosen LJ, Galili T, Kott J, Goodman M, Freedman LS (May 2018). "Diminishing benefit of smoking cessation medications during the first year: a meta-analysis of randomized controlled trials". Addiction. 113 (5): 805–816. doi:10.1111/add.14134. PMC 5947828. PMID 29377409.

^ Livingstone-Banks J, Norris E, Hartmann-Boyce J, West R, Jarvis M, Chubb E, Hajek P (October 2019). "Relapse prevention interventions for smoking cessation". The Cochrane Database of Systematic Reviews. 2019 (10). doi:10.1002/14651858.CD003999.pub6. PMC 6816175. PMID 31684681.

^ Patnode CD, Henderson JT, Coppola EL, Melnikow J, Durbin S, Thomas RG (January 2021). "Interventions for Tobacco Cessation in Adults, Including Pregnant Persons: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force". JAMA. 325 (3): 280–298. doi:10.1001/jama.2020.23541. PMID 33464342.

^ Selph S, Patnode C, Bailey SR, Pappas M, Stoner R, Chou R (April 2020). "Primary Care-Relevant Interventions for Tobacco and Nicotine Use Prevention and Cessation in Children and Adolescents: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force". JAMA. 323 (16): 1599–1608. doi:10.1001/jama.2020.3332. PMID 32343335.

^ Claire R, Chamberlain C, Davey MA, Cooper SE, Berlin I, Leonardi-Bee J, Coleman T (March 2020). "Pharmacological interventions for promoting smoking cessation during pregnancy". The Cochrane Database of Systematic Reviews. 2020 (3): CD010078. doi:10.1002/14651858.CD010078.pub3. PMC 7059898. PMID 32129504.

^ Wolraich ML, Hagan JF, Allan C, Chan E, Davison D, Earls M,  et al. (October 2019). "Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents". Pediatrics. 144 (4): e20192528. doi:10.1542/peds.2019-2528. PMC 7067282. PMID 31570648.

^ a b c d e Verbeeck W, Bekkering GE, Van den Noortgate W, Kramers C (October 2017). "Bupropion for attention deficit hyperactivity disorder (ADHD) in adults". The Cochrane Database of Systematic Reviews. 2017 (10): CD009504. doi:10.1002/14651858.CD009504.pub2. PMC 6485546. PMID 28965364.

^ Elliott J, Johnston A, Husereau D, Kelly SE, Eagles C, Charach A,  et al. (2020). "Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis". PLOS ONE. 15 (10): e0240584. Bibcode:2020PLoSO..1540584E. doi:10.1371/journal.pone.0240584. PMC 7577505. PMID 33085721.

^ Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S,  et al. (September 2018). "Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis". The Lancet. Psychiatry. 5 (9): 727–738. doi:10.1016/S2215-0366(18)30269-4. PMC 6109107. PMID 30097390.

^ Ng QX (March 2017). "A Systematic Review of the Use of Bupropion for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents". Journal of Child and Adolescent Psychopharmacology. 27 (2): 112–116. doi:10.1089/cap.2016.0124. PMID 27813651.

^ a b Wilens TE, Morrison NR, Prince J (October 2011). "An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults". Expert Review of Neurotherapeutics. 11 (10): 1443–1465. doi:10.1586/ern.11.137. PMC 3229037. PMID 21955201.

^ Serretti A, Chiesa A (June 2009). "Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis". Journal of Clinical Psychopharmacology. 29 (3): 259–266. doi:10.1097/JCP.0b013e3181a5233f. PMID 19440080. S2CID 1663570.

^ Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S (2004). "A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor". Primary Care Companion to the Journal of Clinical Psychiatry. 6 (4): 159–166. doi:10.4088/PCC.v06n0403. PMC 514842. PMID 15361919.

^ Basson R, Gilks T (2018). "Women's sexual dysfunction associated with psychiatric disorders and their treatment". Women's Health. 14: 1745506518762664. doi:10.1177/1745506518762664. PMC 5900810. PMID 29649948.

^ Clayton AH, Kingsberg SA, Goldstein I (June 2018). "Evaluation and Management of Hypoactive Sexual Desire Disorder". Sexual Medicine. 6 (2): 59–74. doi:10.1016/j.esxm.2018.01.004. PMC 5960024. PMID 29523488.

^ Goldstein I, Kim NN, Clayton AH, DeRogatis LR, Giraldi A, Parish SJ,  et al. (January 2017). "Hypoactive Sexual Desire Disorder: International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel Review". Mayo Clinic Proceedings. 92 (1): 114–128. doi:10.1016/j.mayocp.2016.09.018. PMID 27916394.

^ a b Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR,  et al. (April 2005). "Meta-analysis: pharmacologic treatment of obesity". Annals of Internal Medicine. 142 (7): 532–546. doi:10.7326/0003-4819-142-7-200504050-00012. PMID 15809465.

^ "Drug Approval Package: Contrave (naltrexone hydrochloride/bupropion hydrochloride) Extended-Release Tablets NDA #200063". U.S. Food and Drug Administration (FDA). Retrieved 5 May 2020.

^ "Contrave Extended-Release - naltrexone hydrochloride and bupropion hydrochloride tablet, extended release". DailyMed. 26 April 2019. Retrieved 5 May 2020.

^ Kampman KM (June 2008). "The search for medications to treat stimulant dependence". Addiction Science & Clinical Practice. 4 (2): 28–35. doi:10.1151/ascp084228. PMC 2797110. PMID 18497715.

^ Cao DN, Shi JJ, Hao W, Wu N, Li J (June 2016). "Advances and challenges in pharmacotherapeutics for amphetamine-type stimulants addiction". European Journal of Pharmacology. 780: 129–135. doi:10.1016/j.ejphar.2016.03.040. PMID 27018393.

^ Mikocka-Walus AA, Turnbull DA, Moulding NT, Wilson IG, Andrews JM, Holtmann GJ (September 2006). "Antidepressants and inflammatory bowel disease: a systematic review". Clinical Practice and Epidemiology in Mental Health. 2: 24. doi:10.1186/1745-0179-2-24. PMC 1599716. PMID 16984660.

^ Thorkelson G, Bielefeldt K, Szigethy E (June 2016). "Empirically Supported Use of Psychiatric Medications in Adolescents and Adults with IBD". Inflammatory Bowel Diseases. 22 (6): 1509–1522. doi:10.1097/MIB.0000000000000734. PMID 27167571.

^ Eskeland S, Halvorsen JA, Tanum L (August 2017). "Antidepressants have Anti-inflammatory Effects that may be Relevant to Dermatology: A Systematic Review". Acta Dermato-Venereologica. 97 (8): 897–905. doi:10.2340/00015555-2702. PMID 28512664.

^ Urquhart DM, Hoving JL, Assendelft WW, Roland M, van Tulder MW (January 2008).  Urquhart DM (ed.). "Antidepressants for non-specific low back pain". The Cochrane Database of Systematic Reviews (1): CD001703. doi:10.1002/14651858.CD001703.pub3. PMC 7025781. PMID 18253994.

^ a b c d e "Drugs@FDA: FDA Approved Drug Products". United States Food and Drug Administration. Retrieved 20 September 2021.

^ "Bupropion/Dextromethorphan - Axsome Therapeutics - AdisInsight".

^ Majeed A, Xiong J, Teopiz KM, Ng J, Ho R, Rosenblat JD,  et al. (March 2021). "Efficacy of dextromethorphan for the treatment of depression: a systematic review of preclinical and clinical trials". Expert Opinion on Emerging Drugs. 26 (1): 63–74. doi:10.1080/14728214.2021.1898588. PMID 33682569. S2CID 232141396.

^ a b c d e f g h "Wellbutrin SR - bupropion hydrochloride tablet, film coated". DailyMed. 5 November 2019. Retrieved 6 May 2020.

^ Alberti S, Chiesa A, Andrisano C, Serretti A (June 2015). "Insomnia and somnolence associated with second-generation antidepressants during the treatment of major depression: a meta-analysis". Journal of Clinical Psychopharmacology. 35 (3): 296–303. doi:10.1097/JCP.0000000000000329. PMID 25874915. S2CID 33102792.

^ Telang S, Walton C, Olten B, Bloch MH (August 2018). "Meta-analysis: Second generation antidepressants and headache". Journal of Affective Disorders. 236: 60–68. doi:10.1016/j.jad.2018.04.047. PMID 29715610. S2CID 19196303.

^ Kittle J, Lopes RD, Huang M, Marquess ML, Wilson MD, Ascher J,  et al. (October 2017). "Cardiovascular adverse events in the drug-development program of bupropion for smoking cessation: A systematic retrospective adjudication effort". Clinical Cardiology. 40 (10): 899–906. doi:10.1002/clc.22744. PMC 6490529. PMID 28605035.

^ Grandi SM, Shimony A, Eisenberg MJ (December 2013). "Bupropion for smoking cessation in patients hospitalized with cardiovascular disease: a systematic review and meta-analysis of randomized controlled trials". The Canadian Journal of Cardiology. 29 (12): 1704–1711. doi:10.1016/j.cjca.2013.09.014. PMID 24267809.

^ Pisani F, Oteri G, Costa C, Di Raimondo G, Di Perri R (2002). "Effects of psychotropic drugs on seizure threshold". Drug Safety. 25 (2): 91–110. doi:10.2165/00002018-200225020-00004. PMID 11888352. S2CID 25290793.

^ Wu A, Khawaja AP, Pasquale LR, Stein JD (January 2020). "A review of systemic medications that may modulate the risk of glaucoma". Eye. 34 (1): 12–28. doi:10.1038/s41433-019-0603-z. PMC 7002596. PMID 31595027.

^ "Naltrexone + bupropion (Mysimba). Too risky for only modest weight loss". Prescrire International. 24 (164): 229–233. October 2015. PMID 26594724.

^ Herstowska M, Komorowska O, Cubała WJ, Jakuszkowiak-Wojten K, Gałuszko-Węgielnik M, Landowski J (May 2014). "Severe skin complications in patients treated with antidepressants: a literature review". Postepy Dermatologii I Alergologii. 31 (2): 92–97. doi:10.5114/pdia.2014.40930. PMC 4112250. PMID 25097474.

^ a b Levenson M, Holland C. "Antidepressants and suicidality in adults: statistical evaluation. (Presentation at Psychopharmacologic Drugs Advisory Committee; December 13, 2006)". U.S. Food and Drug Administration (FDA). Archived from the original on 27 September 2007. Retrieved 13 May 2007.

^ Howes S, Hartmann-Boyce J, Livingstone-Banks J, Hong B, Lindson N (April 2020). "Antidepressants for smoking cessation". The Cochrane Database of Systematic Reviews. 4: CD000031. doi:10.1002/14651858.CD000031.pub5. PMC 7175455. PMID 32319681.

^ Henssler J, Heinz A, Brandt L, Bschor T (May 2019). "Antidepressant Withdrawal and Rebound Phenomena". Deutsches Ärzteblatt International. 116 (20): 355–361. doi:10.3238/arztebl.2019.0355. PMC 6637660. PMID 31288917.

^ Taylor D, Carol P, Shitij K (2012). The Maudsley prescribing guidelines in psychiatry. West Sussex: Wiley-Blackwell. ISBN 978-0-470-97969-3.

^ White N, Litovitz T, Clancy C (December 2008). "Suicidal antidepressant overdoses: a comparative analysis by antidepressant type". Journal of Medical Toxicology. 4 (4): 238–250. doi:10.1007/BF03161207. PMC 3550116. PMID 19031375.

^ a b c d e f Jefferson JW, Pradko JF, Muir KT (November 2005). "Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations". Clinical Therapeutics. 27 (11): 1685–1695. doi:10.1016/j.clinthera.2005.11.011. PMID 16368442.

^ Ketter TA, Jenkins JB, Schroeder DH, Pazzaglia PJ, Marangell LB, George MS,  et al. (October 1995). "Carbamazepine but not valproate induces bupropion metabolism". Journal of Clinical Psychopharmacology. 15 (5): 327–333. doi:10.1097/00004714-199510000-00004. PMID 8830063.

^ a b c https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/200063s015lbl.pdf

^ Todor I, Popa A, Neag M, Muntean D, Bocsan C, Buzoianu A,  et al. (2016). "Evaluation of a Potential Metabolism-Mediated Drug-Drug Interaction Between Atomoxetine and Bupropion in Healthy Volunteers". Journal of Pharmacy & Pharmaceutical Sciences. 19 (2): 198–207. doi:10.18433/J3H03R. PMID 27518170.

^ Schmid Y, Rickli A, Schaffner A, Duthaler U, Grouzmann E, Hysek CM, Liechti ME (April 2015). "Interactions between bupropion and 3,4-methylenedioxymethamphetamine in healthy subjects". The Journal of Pharmacology and Experimental Therapeutics. 353 (1): 102–111. doi:10.1124/jpet.114.222356. PMID 25655950. S2CID 14761997.

^ a b Protti M, Mandrioli R, Marasca C, Cavalli A, Serretti A, Mercolini L (September 2020). "New-generation, non-SSRI antidepressants: Drug-drug interactions and therapeutic drug monitoring. Part 2: NaSSAs, NRIs, SNDRIs, MASSAs, NDRIs, and others". Medicinal Research Reviews. 40 (5): 1794–1832. doi:10.1002/med.21671. PMID 32285503. S2CID 215758102.

^ Spina E, Santoro V, D'Arrigo C (July 2008). "Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update". Clinical Therapeutics. 30 (7): 1206–1227. doi:10.1016/s0149-2918(08)80047-1. PMID 18691982.

^ Feinberg SS (November 2004). "Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication". The Journal of Clinical Psychiatry. 65 (11): 1520–1524. doi:10.4088/jcp.v65n1113. PMID 15554766.

^ Kharasch ED, Neiner A, Kraus K, Blood J, Stevens A, Schweiger J,  et al. (May 2019). "Bioequivalence and Therapeutic Equivalence of Generic and Brand Bupropion in Adults With Major Depression: A Randomized Clinical Trial". Clinical Pharmacology and Therapeutics. 105 (5): 1164–1174. doi:10.1002/cpt.1309. PMC 6465131. PMID 30460996.

^ Kharasch ED, Neiner A, Kraus K, Blood J, Stevens A, Miller JP, Lenze EJ (November 2020). "Stereoselective Steady-State Disposition and Bioequivalence of Brand and Generic Bupropion in Adults". Clinical Pharmacology and Therapeutics. 108 (5): 1036–1048. doi:10.1002/cpt.1888. PMID 32386065. S2CID 218563059.

^ a b c d e Lukas RJ, Muresan AZ, Damaj MI, Blough BE, Huang X, Navarro HA,  et al. (June 2010). "Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation". Journal of Medicinal Chemistry. 53 (12): 4731–4748. doi:10.1021/jm1003232. PMC 2895766. PMID 20509659.

^ a b c Sánchez C, Hyttel J (August 1999). "Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding". Cellular and Molecular Neurobiology. 19 (4): 467–489. doi:10.1023/a:1006986824213. PMID 10379421. S2CID 19490821.

^ Bondarev ML, Bondareva TS, Young R, Glennon RA (August 2003). "Behavioral and biochemical investigations of bupropion metabolites". European Journal of Pharmacology. 474 (1): 85–93. doi:10.1016/S0014-2999(03)02010-7. PMID 12909199.

^ a b Damaj MI, Carroll FI, Eaton JB, Navarro HA, Blough BE, Mirza S,  et al. (September 2004). "Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors". Molecular Pharmacology. 66 (3): 675–682. doi:10.1124/mol.104.001313. PMID 15322260. S2CID 1577336.

^ a b c d Eap CB, Gründer G, Baumann P, Ansermot N, Conca A, Corruble E,  et al. (October 2021). "Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants". The World Journal of Biological Psychiatry. 22 (8): 561–628. doi:10.1080/15622975.2021.1878427. PMID 33977870. S2CID 234472488.

^ a b c Carroll FI, Blough BE, Mascarella SW, Navarro HA, Lukas RJ, Damaj MI (2014). "Bupropion and bupropion analogs as treatments for CNS disorders". Emerging Targets & Therapeutics in the Treatment of Psychostimulant Abuse. Adv Pharmacol. Advances in Pharmacology. Vol. 69. pp. 177–216. doi:10.1016/B978-0-12-420118-7.00005-6. ISBN 9780124201187. PMID 24484978.

^ Gründer G, Hiemke C, Paulzen M, Veselinovic T, Vernaleken I (September 2011). "Therapeutic plasma concentrations of antidepressants and antipsychotics: lessons from PET imaging". Pharmacopsychiatry. 44 (6): 236–248. doi:10.1055/s-0031-1286282. PMID 21959785.

^ Brunton L, Chabner B, Knollman B (2010). Goodman and Gilman's The Pharmacological Basis of Therapeutics (12th ed.). New York: McGraw-Hill Professional. ISBN 978-0-07-162442-8.[page needed]

^ Hesse LM, He P, Krishnaswamy S, Hao Q, Hogan K, von Moltke LL,  et al. (April 2004). "Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes". Pharmacogenetics. 14 (4): 225–238. doi:10.1097/00008571-200404000-00002. PMID 15083067.

^ Preskorn SH (1991). "Should bupropion dosage be adjusted based upon therapeutic drug monitoring?". Psychopharmacology Bulletin. 27 (4): 637–643. PMID 1813908.

^ Musso DL, Mehta NB, Soroko FE, Ferris RM, Hollingsworth EB, Kenney BT (1993). "Synthesis and evaluation of the antidepressant activity of the enantiomers of bupropion". Chirality. 5 (7): 495–500. doi:10.1002/chir.530050704. PMID 8240925.

^ Weintraub D, Linder MW (2000). "Amphetamine positive toxicology screen secondary to bupropion". Depression and Anxiety. 12 (1): 53–54. doi:10.1002/1520-6394(2000)12:1<53::AID-DA8>3.0.CO;2-4. PMID 10999247.

^ Nixon AL, Long WH, Puopolo PR, Flood JG (June 1995). "Bupropion metabolites produce false-positive urine amphetamine results". Clinical Chemistry. 41 (6 Pt 1): 955–956. doi:10.1093/clinchem/41.6.955. PMID 7768026.

^ Casey ER, Scott MG, Tang S, Mullins ME (June 2011). "Frequency of false positive amphetamine screens due to bupropion using the Syva EMIT II immunoassay". Journal of Medical Toxicology. 7 (2): 105–108. doi:10.1007/s13181-010-0131-5. PMC 3724447. PMID 21191682.

^ Perrine DM, Ross JT, Nervi SJ, Zimmerman RH (2000). "A Short, One-Pot Synthesis of Bupropion (Zyban, Wellbutrin)". Journal of Chemical Education. 77 (11): 1479. Bibcode:2000JChEd..77.1479P. doi:10.1021/ed077p1479.

^ Fava M, Rush AJ, Thase ME, Clayton A, Stahl SM, Pradko JF, Johnston JA (2005). "15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL". Primary Care Companion to the Journal of Clinical Psychiatry. 7 (3): 106–113. doi:10.4088/pcc.v07n0305. PMC 1163271. PMID 16027765.

^ "Wellbutrin entry in the Orange Book". U.S. Food and Drug Administration Center for Drug Evaluation and Research. Archived from the original on 25 February 2011. Retrieved 18 August 2007.

^ "Bupropion (Wellbutrin)". eMedExpert.com. 31 March 2008. Retrieved 20 August 2013.

^ a b Whitten L (April 2006). "Bupropion helps people with schizophrenia quit smoking". National Institute on Drug Abuse Research Findings. 20 (5). Archived from the original on 5 August 2007. Retrieved 27 May 2013.

^ "Drug Approval Package: Wellbutrin XL (Bupropion HCI) NDA #021515". U.S. Food and Drug Administration (FDA). 22 April 2005. Archived from the original on 5 December 2019. Retrieved 4 December 2019.

^ "Drug Approval Package: Zyban NDA# 020711". U.S. Food and Drug Administration (FDA). 8 August 2003. Archived from the original on 5 December 2019. Retrieved 4 December 2019.

^ "FDA approval letter" (PDF). U.S. Food and Drug Administration (FDA). 6 December 2006.

^ "Seasonal affective disorder drug Wellbutrin XL wins approval". CNN. 14 June 2006. Archived from the original on 30 June 2007. Retrieved 19 August 2007.

^ "Zyban : sevrage tabagique et sécurité d'emploi" [Zyban: smoking cessation and job security] (Press release) (in French). Agence française de sécurité sanitaire des produits de santé. 18 January 2002. Archived from the original on 23 July 2011. Retrieved 25 January 2011.

^ "Generic drug equality questioned". 12 October 2007. Archived from the original on 3 October 2012. Retrieved 13 October 2007.

^ Stenson J (12 October 2007). "Report questions generic antidepressant". NBC News. Retrieved 13 October 2007.

^ "Review of therapeutic equivalence: generic bupropion XL 300 mg and Wellbutrin XL 300 mg". Food and Drug Administration. Archived from the original on 6 June 2011. Retrieved 19 April 2008.

^ a b c "Budeprion XL 300 mg not therapeutically equivalent to Wellbutrin XL 300 mg". U.S. Food and Drug Administration (FDA). 3 October 2012. Retrieved 23 March 2013.  This article incorporates text from this source, which is in the public domain.

^ Waknine Y (8 May 2008). "FDA Approvals: Advair, Relistor, Aplenzin". Medscape. Retrieved 9 May 2008.

^ "Drug Approval Package: Aplenzin (Bupropion Hydrobromide) NDA 22108". U.S. Food and Drug Administration (FDA). 24 December 1999. Retrieved 5 May 2020.

^ "Aplenzin - bupropion hydrobromide tablet, extended release". DailyMed. 2 June 2020. Retrieved 21 October 2020.

^ "Public Health Advisory: FDA requires new boxed warnings for the smoking cessation drugs Chantix and Zyban". U.S. Food and Drug Administration (FDA). 1 July 2009. Archived from the original on 19 October 2010. Retrieved 3 July 2009.

^ "The smoking cessation aids varenicline (marketed as Chantix) and bupropion (marketed as Zyban and generics) suicidal ideation and behavior" (PDF). Drug Safety Newsletter. 2 (1): 1–4. 2009. Archived from the original (PDF) on 11 February 2017. Retrieved 16 December 2019.

^ "Safety Alerts for Human Medical Products - Chantix (varenicline) and Zyban (bupropion): Drug Safety Communication – Mental Health Side Effects Revised". U.S. Food and Drug Administration (FDA). Archived from the original on 20 December 2016. Retrieved 20 December 2016.

^ Thomas K, Schmidt MS (2 July 2012). "Glaxo agrees to pay $3 billion in fraud settlement". The New York Times.

^ "EMA recommends suspension of medicines due to unreliable studies from Micro Therapeutic Research Labs | European Medicines Agency".

^ "Products for which the marketing authorisations are recommended for suspension and marketing authorisation applications which do not satisfy the criteria for authorisation as adopted by the CHMP on 23 March 2017" (PDF).

^ a b Naglich AC, Brown ES, Adinoff B (2019). "Systematic review of preclinical, clinical, and post-marketing evidence of bupropion misuse potential". The American Journal of Drug and Alcohol Abuse. 45 (4): 341–354. doi:10.1080/00952990.2018.1545023. PMID 30601027. S2CID 58587857.

^ Lile JA, Nader MA (2003). "The abuse liability and therapeutic potential of drugs evaluated for cocaine addiction as predicted by animal models". Current Neuropharmacology. 1: 21–46. CiteSeerX 10.1.1.325.9635. doi:10.2174/1570159033360566.

^ Antidepressant Wellbutrin becomes 'poor man's cocaine' on Toronto streets Global News 18 September 2013.

^ Phillips D (February 2012). "Wellbutrin®: misuse and abuse by incarcerated individuals". Journal of Addictions Nursing. 23 (1): 65–69. doi:10.3109/10884602.2011.647838. PMID 22468662. S2CID 1310940.

^ Baribeau D, Araki KF (May–June 2013). "Intravenous bupropion: a previously undocumented method of abuse of a commonly prescribed antidepressant agent". Journal of Addiction Medicine. 7 (3): 216–217. doi:10.1097/ADM.0b013e3182824863. PMID 23519045.

^ Stassinos GL, Klein-Schwartz W (2016). "Bupropion "Abuse" Reported to US Poison Centers". Journal of Addiction Medicine. 10 (5): 357–362. doi:10.1097/ADM.0000000000000249. PMID 27504927. S2CID 24870292.

^ "Постановление Правительства РФ от 30 июня 1998 г. N 681 "Об утверждении перечня наркотических средств, психотропных веществ и их прекурсоров, подлежащих контролю в Российской Федерации" (с изменениями и дополнениями)" (in Russian). Гарант. Retrieved 28 April 2019. Эфедрон (меткатинон) и его производные, за исключением производных, включенных в качестве самостоятельных позиций в перечень

^ Rossi S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN 978-0-9805790-9-3.

^ Joint Formulary Committee (2015). British National Formulary (BNF) (69 ed.). London, UK: Pharmaceutical Press. ISBN 978-0-85711-156-2.


External links[edit]



Wikimedia Commons has media related to Bupropion.

"Bupropion". Drug Information Portal. U.S. National Library of Medicine.
"Bupropion hydrochloride". Drug Information Portal. U.S. National Library of Medicine.
"Bupropion hydrobromide". Drug Information Portal. U.S. National Library of Medicine.


.mw-parser-output .navbox{box-sizing:border-box;border:1px solid #a2a9b1;width:100%;clear:both;font-size:88%;text-align:center;padding:1px;margin:1em auto 0}.mw-parser-output .navbox .navbox{margin-top:0}.mw-parser-output .navbox+.navbox,.mw-parser-output .navbox+.navbox-styles+.navbox{margin-top:-1px}.mw-parser-output .navbox-inner,.mw-parser-output .navbox-subgroup{width:100%}.mw-parser-output .navbox-group,.mw-parser-output .navbox-title,.mw-parser-output .navbox-abovebelow{padding:0.25em 1em;line-height:1.5em;text-align:center}.mw-parser-output .navbox-group{white-space:nowrap;text-align:right}.mw-parser-output .navbox,.mw-parser-output .navbox-subgroup{background-color:#fdfdfd}.mw-parser-output .navbox-list{line-height:1.5em;border-color:#fdfdfd}.mw-parser-output .navbox-list-with-group{text-align:left;border-left-width:2px;border-left-style:solid}.mw-parser-output tr+tr>.navbox-abovebelow,.mw-parser-output tr+tr>.navbox-group,.mw-parser-output tr+tr>.navbox-image,.mw-parser-output tr+tr>.navbox-list{border-top:2px solid #fdfdfd}.mw-parser-output .navbox-title{background-color:#ccf}.mw-parser-output .navbox-abovebelow,.mw-parser-output .navbox-group,.mw-parser-output .navbox-subgroup .navbox-title{background-color:#ddf}.mw-parser-output .navbox-subgroup .navbox-group,.mw-parser-output .navbox-subgroup .navbox-abovebelow{background-color:#e6e6ff}.mw-parser-output .navbox-even{background-color:#f7f7f7}.mw-parser-output .navbox-odd{background-color:transparent}.mw-parser-output .navbox .hlist td dl,.mw-parser-output .navbox .hlist td ol,.mw-parser-output .navbox .hlist td ul,.mw-parser-output .navbox td.hlist dl,.mw-parser-output .navbox td.hlist ol,.mw-parser-output .navbox td.hlist ul{padding:0.125em 0}.mw-parser-output .navbox .navbar{display:block;font-size:100%}.mw-parser-output .navbox-title .navbar{float:left;text-align:left;margin-right:0.5em}.mw-parser-output .navbar{display:inline;font-size:88%;font-weight:normal}.mw-parser-output .navbar-collapse{float:left;text-align:left}.mw-parser-output .navbar-boxtext{word-spacing:0}.mw-parser-output .navbar ul{display:inline-block;white-space:nowrap;line-height:inherit}.mw-parser-output .navbar-brackets::before{margin-right:-0.125em;content:"[ "}.mw-parser-output .navbar-brackets::after{margin-left:-0.125em;content:" ]"}.mw-parser-output .navbar li{word-spacing:-0.125em}.mw-parser-output .navbar a>span,.mw-parser-output .navbar a>abbr{text-decoration:inherit}.mw-parser-output .navbar-mini abbr{font-variant:small-caps;border-bottom:none;text-decoration:none;cursor:inherit}.mw-parser-output .navbar-ct-full{font-size:114%;margin:0 7em}.mw-parser-output .navbar-ct-mini{font-size:114%;margin:0 4em}vteAntidepressants (N06A)Specific reuptake inhibitors and/or receptor modulatorsSSRIs
Citalopram
Escitalopram
Fluoxetine#
Fluvoxamine
Indalpine‡
Paroxetine
Sertraline
Zimelidine‡
SNRIs
Desvenlafaxine
Duloxetine
Levomilnacipran
Milnacipran
Tofenacin
Venlafaxine
NRIs
Atomoxetine
Reboxetine
Viloxazine
NDRIs
Amineptine‡
Bupropion
Nomifensine‡
NaSSAs
Mianserin
Mirtazapine
Setiptiline
SARIs
Etoperidone
Nefazodone
Trazodone
SMS
Vilazodone
Vortioxetine
Others
Agomelatine
Amisulpride
Esketamine
Etryptamine‡
Indeloxazine
flupentixol
Ketamine§
Medifoxamine‡
Metryptamine‡
Oxaflozane‡
Pivagabine‡
Tandospirone
Teniloxazine
Tianeptine
Tricyclic and tetracyclic antidepressantsTCAs
Amineptine‡
Amitriptyline#
Amitriptylinoxide
Butriptyline‡
Clomipramine#
Demexiptiline‡
Desipramine
Dibenzepin
Dimetacrine‡
Dosulepin
Doxepin
Imipramine
Imipraminoxide‡
Iprindole‡
Lofepramine
Melitracen
Metapramine‡
Nitroxazepine
Nortriptyline
Noxiptiline
Opipramol
Pipofezine
Propizepine‡
Protriptyline
Quinupramine‡
Tianeptine
Trimipramine
TeCAs
Amoxapine
Maprotiline
Mianserin
Mirtazapine
Setiptiline
Others
Tiazesim
Monoamine oxidase inhibitorsNon-selective
Irreversible: Benmoxin‡
Iproclozide‡
Iproniazid‡
Isocarboxazid
Isoniazid#
Linezolid#
Mebanazine‡
Nialamide‡
Octamoxin‡
Phenelzine
Pheniprazine‡
Phenoxypropazine‡
Pivhydrazine‡
Safrazine‡
Tedizolid
Tranylcypromine
Reversible: Caroxazone‡
Mixed: Bifemelane
MAOA-selective
Reversible: Eprobemide
Metralindole
Minaprine‡
Moclobemide
Pirlindole
Tetrindole
Toloxatone
MAOB-selective
Irreversible: Selegiline
Adjunctive therapies
Atypical antipsychotics (aripiprazole, brexpiprazole, lurasidone, olanzapine, quetiapine, risperidone)
Buspirone
Lithium (lithium carbonate, lithium citrate)
Thyroid hormones (triiodothyronine (T3), levothyroxine (T4))
Miscellaneous
Ademetionine (SAMe)
Hypericum perforatum (St. John's Wort)
Oxitriptan (5-HTP)
Rubidium chloride (RbCl)
Tryptophan

#WHO-EM
‡Withdrawn from market
Clinical trials:
†Phase III
§Never to phase III

vteTreatment of drug dependence (N07B)Nicotine dependence
Bupropion#
Cytisine
Lobeline
Mecamylamine
Varenicline
AA (Clonidine)
Alcohol dependence
AD inhibitor (Disulfiram
Calcium carbimide
Hydrogen cyanamide)
Acamprosate
Opioid antagonists
Naltrexone
Nalmefene)
Topiramate
AA (Clonidine)
Baclofen
Phenibut
Opioid dependence
AA (Clonidine
Lofexidine)
Ibogaine
Opioids
Buprenorphine (+naloxone)
Levacetylmethadol
Methadone
Dihydrocodeine
Dihydroetorphine
Hydromorphone (extended-release)
Morphine (extended-release)
Opioid antagonists (Naltrexone
Nalmefene)
Benzodiazepine dependence
AA (Clonidine)
Benzodiazepines (Diazepam
Lorazepam
Chlordiazepoxide
Oxazepam)
Barbiturates (Phenobarbital)

vteAntiobesity agents/Anorectics (A08)CentralStimulants
4-Methylamphetamine‡
Amfecloral
Amfepentorex
Amfepramone
Aminorex‡
Amphetamine
Amphetaminil
Atomoxetine
Benfluorex‡
Benzphetamine
Bupropion (+naltrexone; +zonisamide†)
Cathine
Cathinone
Chlorphentermine
Ciclazindol
Clobenzorex
Cloforex
Clominorex
Clortermine
Dexfenfluramine‡
Dextroamphetamine
Dexmethylphenidate
Difemetorex‡
Dimethylcathinone
Ephedrine
Ephedra‡
Etilamfetamine
Etolorex
Fenbutrazate
Fencamfamin
Fenethylline
Fenfluramine (+phentermine‡)
Fenproporex
Fludorex
Fluminorex
Furfenorex‡
Indanorex
Khat
Levopropylhexedrine
Lisdexamfetamine
Manifaxine
Mazindol
Mefenorex
Methamphetamine
Methylphenidate
Norfenfluramine
Pemoline
Pentorex
Phendimetrazine
Phenethylamine
Phenmetrazine
Phentermine (+topiramate)
Phenylpropanolamine
Picilorex
Pipradrol
Prolintane
Propylhexedrine
Pseudoephedrine
Pyrovalerone
Radafaxine
Reboxetine
Setazindol
Sibutramine‡
Synephrine
Tesofensine
Viloxazine
Xylopropamine
Zylofuramine
Cannabinoidreceptor antagonists
Drinabant§
Ibipinabant§
Otenabant§
Rimonabant‡
Rosonabant§
Surinabant§
Taranabant§
Others
5-HTP
Beloranib§
Galactomannan
Guar gum
Glucomannan
L-DOPA
L-Phenylalanine
L-Tryptophan
L-Tyrosine
Lorcaserin
Lu AA-33810
Metformin
Naltrexone
Naloxone
Oxyntomodulin
P57
Peptide YY
Setmelanotide
Topiramate
Velneperit§
Yohimbine (Yohimbe)
Zonisamide
Water
Peripheral
Cetilistat
2,4-Dinitrophenol‡
Dirlotapide
Gelesis100
Mitratapide
Oleoyl-estrone
Orlistat
Simmondsin
Sterculia

#WHO-EM
‡Withdrawn from market
Clinical trials:
†Phase III
§Never to phase III

vteSexual dysfunction pharmacotherapiesDopamine agonists
Apomorphine
Cabergoline
Lisuride
Pergolide
Piribedil
Pramipexole
Quinagolide
Ropinirole
Rotigotine
Terguride
Melanocortin agonists
Bremelanotide
Melanotan II
PL-6983
PDE5 inhibitors
Acetildenafil
Aildenafil
Avanafil
Icariin
Lodenafil
Mirodenafil
Nitrosoprodenafil
Sildenafil
Sulfoaildenafil
Tadalafil
Udenafil
Vardenafil
Sex steroids
Androgens (e.g., testosterone, methyltestosterone, other anabolic steroids)
Estrogens (e.g., estradiol, ethinylestradiol, conjugated equine estrogens (Premarin))
Progestogens (e.g., progesterone, progestins)
Mixed (e.g., tibolone)
Others
Afrodor (acecarbromal, quebracho, vitamin E)
Alkyl nitrites
Alprostadil
Amantadine
Bupropion
Buspirone
Cyproheptadine
Dapoxetine
Flibanserin
Mirtazapine
Moxisylyte
Oxytocin
Papaverine
Phentolamine
Psychostimulants (e.g., amphetamines, cocaine, methylphenidate)
Rauwolscine (Rauvolfia)
Trazodone
Yohimbine (Yohimbe)

See also: Drugs for erectile dysfunction and premature ejaculation

vteMonoamine reuptake inhibitorsDAT(DRIs)
Piperazines: DBL-583
GBR-12783
GBR-12935
GBR-13069
GBR-13098
Nefazodone
Vanoxerine

Piperidines: 4-Fluoropethidine
Benocyclidine (BTCP)
Desoxypipradrol
Dexmethylphenidate
Difemetorex
Ethylphenidate
HDMP-28
Methylphenidate
Pethidine (meperidine)
Phencyclidine
Pipradrol
Serdexmethylphenidate
Tenocyclidine

Pyrrolidines: Diphenylprolinol
MDPV
Naphyrone
Prolintane
Pyrovalerone

Tropanes: Altropane
Benzatropine (benztropine)
Brasofensine
CFT
Cocaine
Dichloropane
Difluoropine
Etybenzatropine (ethybenztropine)
FE-β-CPPIT
FP-β-CPPIT
Ioflupane (123I)
RTI-55
RTI-112
RTI-113
RTI-121
RTI-126
RTI-150
RTI-177
RTI-229
RTI-336
Tesofensine
Troparil
Tropoxane
WF-11
WF-23
WF-31
WF-33

Others: Adrafinil
Amifitadine
Armodafinil
Amfonelic acid
Amineptine
Ansofaxine
BTQ
BTS 74,398
Bupropion
Chaenomeles speciosa
Ciclazindol
Dasotraline
Desmethylsertraline
Desmethylsibutramine (BTS-54354)
Diclofensine
Didesmethylsibutramine (BTS-54505)
Dimethocaine
Diphenylpyraline
Dizocilpine (MK-801)
DOV-102,677
DOV-216,303
Efavirenz
Ephenidine
Esketamine
EXP-561
Fencamfamin
Fezolamine
Fluorenol
GYKI-52895
Indatraline
Ketamine
Lefetamine
Levophacetoperane
Liafensine
LR-5182
Manifaxine
Mazindol
Medifoxamine
Mesocarb
Metaphit
MIN-117 (WF-516)
Modafinil
Nefopam
Nomifensine
NS-2359
O-2172
Oroxylin A
Perafensine
Pridefine
Radafaxine
Rimcazole
Sertraline
Sibutramine
Solriamfetol
Tametraline
Tedatioxetine
Tripelennamine
Venlafaxine
NET(NRIs)
Selective norepinephrine reuptake inhibitors: Amedalin
Alseroxylon
Ciclazindol
Daledalin
Edivoxetine
Esreboxetine
Lortalamine
Mazindol
Nisoxetine
Reboxetine
Talopram
Talsupram
Tandamine
Teniloxazine
Viloxazine

Norepinephrine–dopamine reuptake inhibitors: Amineptine
Bupropion
Fencamine
Fencamfamin
Hydroxybupropion
Lefetamine
Levophacetoperane
LR-5182
Manifaxine
Methylphenidate
Nomifensine
O-2172
Radafaxine
Serdexmethylphenidate
Solriamfetol

Serotonin–norepinephrine reuptake inhibitors: Atomoxetine (tomoxetine)
CP-39,332
Desvenlafaxine
Duloxetine
Eclanamine
Levomilnacipran
McN5652
Milnacipran
N-Methyl-PPPA
Nafenodone
PPPA
Tofenacin
Venlafaxine

Serotonin–norepinephrine–dopamine reuptake inhibitors: 3,3-Diphenylcyclobutanamine
Amifitadine
Ansofaxine
Bicifadine
Brasofensine
Centanafadine
Cocaine
Dasotraline
Desmethylsertraline
Desmethylsibutramine (BTS-54354)
Diclofensine
Didesmethylsibutramine (BTS-54505)
DOV-102677
DOV-216303
EXP-561
Fezolamine
HDMP-28
Indatraline
JNJ-7925476
JZ-IV-10
Liafensine
Mazindol
Naphyrone
Nefazodone
Nefopam
NS-2359
Perafensine
PRC200
Pridefine
SEP-228431
SEP-228432
Sibutramine
Tedatioxetine
Tesofensine
Tropanes (e.g., cocaine)

Tricyclic antidepressants: Amitriptyline
Butriptyline
Cianopramine
Clomipramine
Desipramine
Dosulepin (dothiepin)
Doxepin
Imipramine
Lofepramine
Melitracen
Nortriptyline
Protriptyline
Trimipramine

Tetracyclic antidepressants: Amoxapine
Maprotiline
Mianserin
Oxaprotiline
Setiptiline

Others: Antihistamines (e.g., brompheniramine, chlorphenamine, pheniramine, tripelennamine)
Antipsychotics (e.g., loxapine, ziprasidone)
Arylcyclohexylamines (e.g., ketamine, phencyclidine)
Dopexamine
Ephenidine
Ginkgo biloba
Indeloxazine
Nefazodone
Opioids (e.g., desmetramadol, methadone, pethidine (meperidine), tapentadol, tramadol, levorphanol)
SERT(SRIs)
Selective serotonin reuptake inhibitors: 6-Nitroquipazine
Alaproclate
Centpropazine
Cericlamine
Citalopram
Dapoxetine
Desmethylcitalopram
Didesmethylcitalopram
Escitalopram
Femoxetine
Fluoxetine
Fluvoxamine
Indalpine
Ifoxetine
Norfluoxetine
Omiloxetine
Panuramine
Paroxetine
PIM-35
Pirandamine
RTI-353
Seproxetine
Sertraline
Zimelidine
Selective serotonin reuptake inhibitors and serotonin receptor modulators: Etoperidone
Litoxetine
Lubazodone
LY-393558
Quipazine
SB-649915
TGBA01AD
Trazodone
Vilazodone
Vortioxetine

Serotonin–norepinephrine reuptake inhibitors: Atomoxetine (tomoxetine)
Bicifadine
CP-39332
Desvenlafaxine
Duloxetine
Eclanamine
Levomilnacipran
McN5652
Milnacipran
N-Methyl-PPPA
PPPA
Tofenacin
Venlafaxine

Serotonin–norepinephrine–dopamine reuptake inhibitors: 3,3-Diphenylcyclobutanamine
Amifitadine
Ansofaxine
Bicifadine
Brasofensine
Centanafadine
Cocaine
Dasotraline
Desmethylsertraline
Desmethylsibutramine (BTS-54354)
Diclofensine
Didesmethylsibutramine (BTS-54505)
DOV-102677
DOV-216303
EXP-561
Fezolamine
HDMP-28
Indatraline
JNJ-7925476
JZ-IV-10
Liafensine
Mazindol
Naphyrone
Nefazodone
Nefopam
NS-2359
Perafensine
PRC200
Pridefine
SEP-228431
SEP-228432
Sibutramine
Tedatioxetine
Tesofensine
Tropanes (e.g., cocaine)

Tricyclic antidepressants: Amitriptyline
Cianopramine
Clomipramine
Cyanodothiepin
Desipramine
Dosulepin (dothiepin)
Doxepin
Imipramine
Lofepramine
Nortriptyline
Pipofezine
Protriptyline

Others: A-80426
Amoxapine
Antihistamines (e.g., brompheniramine, chlorphenamine, dimenhydrinate, diphenhydramine, mepyramine (pyrilamine), pheniramine, tripelennamine)
Antipsychotics (e.g., loxapine, ziprasidone)
Arylcyclohexylamines (e.g., 3-MeO-PCP, esketamine, ketamine, methoxetamine, phencyclidine)
Cyclobenzaprine
Delucemine
Dextromethorphan
Dextrorphan
Efavirenz
Hypidone
Medifoxamine
Mesembrine
Mifepristone
MIN-117 (WF-516)
N-Me-5-HT
Opioids (e.g., dextropropoxyphene, methadone, pethidine (meperidine), levorphanol, tapentadol, tramadol)
Roxindole
VMATs
Amiodarone
Amphetamines (e.g., amphetamine, methamphetamine, MDMA)
APP
AZIK
Bietaserpine
Deserpidine
Deutetrabenazine
Dihydrotetrabenazine
Efavirenz
GBR-12935
GZ-793A
Ibogaine
Ketanserin
Lobeline
Methoxytetrabenazine
Reserpine
Rose bengal
Tetrabenazine
Valbenazine
Vanoxerine (GBR-12909)
Others
DAT enhancers: Luteolin
DAT modulators: Agonist-like: SoRI-9804
SoRI-20040; Antagonist-like: SoRI-20041
See also: Receptor/signaling modulators • Monoamine releasing agents • Adrenergics • Dopaminergics • Serotonergics • Monoamine metabolism modulators • Monoamine neurotoxins
vteNicotinic acetylcholine receptor modulatorsnAChRsAgonists(and PAMs)
5-HIAA
6-Chloronicotine
A-84,543
A-366,833
A-582,941
A-867,744
ABT-202
ABT-418
ABT-560
ABT-894
Acetylcholine
Altinicline
Anabasine
Anatabine
Anatoxin-a
AR-R17779
Bephenium hydroxynaphthoate
Butinoline
Butyrylcholine
Carbachol
Choline
Cotinine
Cytisine
Decamethonium
Desformylflustrabromine
Dianicline
Dimethylphenylpiperazinium
Epibatidine
Epiboxidine
Ethanol (alcohol)
Ethoxysebacylcholine
EVP-4473
EVP-6124
Galantamine
GTS-21
Ispronicline
Ivermectin
JNJ-39393406
Levamisole
Lobeline
MEM-63,908 (RG-3487)
Morantel
Nicotine (tobacco)
NS-1738
PHA-543,613
PHA-709,829
PNU-120,596
PNU-282,987
Pozanicline
Pyrantel
Rivanicline
RJR-2429
Sazetidine A
SB-206553
Sebacylcholine
SIB-1508Y
SIB-1553A
SSR-180,711
Suberyldicholine
Suxamethonium (succinylcholine)
Suxethonium (succinyldicholine)
TC-1698
TC-1734
TC-1827
TC-2216
TC-5214
TC-5619
TC-6683
Tebanicline
Tribendimidine
Tropisetron
UB-165
Varenicline
WAY-317,538
XY-4083
Antagonists(and NAMs)
18-MAC
18-MC
α-Neurotoxins (e.g., α-bungarotoxin, α-cobratoxin, α-conotoxin, many others)
ABT-126
Alcuronium
Allopregnanolone
Amantadine
Anatruxonium
AQW051
Atracurium
Barbiturates (e.g., pentobarbital, sodium thiopental)
BNC-210
Bungarotoxins (e.g., α-bungarotoxin, κ-bungarotoxin)
Bupropion
BW284C51
BW-A444
Candocuronium iodide (chandonium iodide)
Chlorisondamine
Cisatracurium
Coclaurine
Coronaridine
Curare
Cyclopropane
Dacuronium bromide
Decamethonium
Dehydronorketamine
Desflurane
Dextromethorphan
Dextropropoxyphene
Dextrorphan
Diadonium
DHβE
Dihydrochandonium
Dimethyltubocurarine (metocurine)
Dioscorine
Dipyrandium
Dizocilpine (MK-801)
Doxacurium
Encenicline
Enflurane
Erythravine
Esketamine
Fazadinium
Gallamine
Gantacurium chloride
Halothane
Hexafluronium
Hexamethonium (benzohexonium)
Hydroxybupropion
Hydroxynorketamine
Ibogaine
Isoflurane
Ketamine
Kynurenic acid
Laudanosine
Laudexium (laudolissin)
Levacetylmethadol
Levomethadone
Malouetine
ME-18-MC
Mecamylamine
Memantine
Methadone
Methorphan (racemethorphan)
Methyllycaconitine
Metocurine
Mivacurium
Morphanol (racemorphan)
Neramexane
Nitrous oxide
Norketamine
Pancuronium bromide
Pempidine
Pentamine
Pentolinium
Phencyclidine
Pipecuronium bromide
Progesterone
Promegestone
Radafaxine
Rapacuronium bromide
Reboxetine
Rocuronium bromide
Sevoflurane
Stercuronium iodide
Surugatoxin
Thiocolchicoside
Toxiferine
Tramadol
Trimetaphan camsilate (trimethaphan camsylate)
Tropeinium
Tubocurarine
Vanoxerine
Vecuronium bromide
Xenon
Precursors(and prodrugs)
Acetyl-coA
Adafenoxate
Choline (lecithin)
Citicoline
Cyprodenate
Dimethylethanolamine
Glycerophosphocholine
Meclofenoxate (centrophenoxine)
Phosphatidylcholine
Phosphatidylethanolamine
Phosphorylcholine
Pirisudanol
See also: Receptor/signaling modulators • Muscarinic acetylcholine receptor modulators • Acetylcholine metabolism/transport modulators
vteSerotonin receptor modulators5-HT15-HT1A
Agonists: 8-OH-DPAT
Adatanserin
Amphetamine
Antidepressants (e.g., etoperidone, hydroxynefazodone, nefazodone, trazodone, triazoledione, vilazodone, vortioxetine)
Atypical antipsychotics (e.g., aripiprazole, asenapine, brexpiprazole, cariprazine, clozapine, lurasidone, quetiapine, ziprasidone)
Azapirones (e.g., buspirone, eptapirone, gepirone, perospirone, tandospirone)
Bay R 1531
Befiradol
BMY-14802
Cannabidiol
Dimemebfe
Dopamine
Ebalzotan
Eltoprazine
Enciprazine
Ergolines (e.g., bromocriptine, cabergoline, dihydroergotamine, ergotamine, lisuride, LSD, methylergometrine (methylergonovine), methysergide, pergolide)
F-11461
F-12826
F-13714
F-14679
F-15063
F-15,599
Flesinoxan
Flibanserin
Flumexadol
Hypidone
Lesopitron
LY-293284
LY-301317
mCPP
MKC-242
Naluzotan
NBUMP
Osemozotan
Oxaflozane
Pardoprunox
Piclozotan
Rauwolscine
Repinotan
Roxindole
RU-24,969
S-14,506
S-14671
S-15535
Sarizotan
Serotonin (5-HT)
SSR-181507
Sunepitron
Tryptamines (e.g., 5-CT, 5-MeO-DMT, 5-MT, bufotenin, DMT, indorenate, N-Me-5-HT, psilocin, psilocybin)
TGBA01AD
U-92,016-A
Urapidil
Vilazodone
Xaliproden
Yohimbine

Antagonists: Atypical antipsychotics (e.g., iloperidone, risperidone, sertindole)
AV965
Beta blockers (e.g., alprenolol, carteolol, cyanopindolol, iodocyanopindolol, isamoltane, oxprenolol, penbutolol, pindobind, pindolol, propranolol, tertatolol)
BMY-7,378
CSP-2503
Dotarizine
Ergolines (e.g., metergoline)
FCE-24379
Flopropione
GR-46611
Isamoltane
Lecozotan
Mefway
Metitepine (methiothepin)
MIN-117 (WF-516)
MPPF
NAN-190
Robalzotan
S-15535
SB-649,915
SDZ 216-525
Spiperone
Spiramide
Spiroxatrine
UH-301
WAY-100135
WAY-100635
Xylamidine

Unknown/unsorted: Acetryptine
Carvedilol
Ergolines (e.g., ergometrine (ergonovine))
5-HT1B
Agonists: Anpirtoline
CGS-12066A
CP-93129
CP-94253
CP-122,288
CP-135807
Eltoprazine
Ergolines (e.g., bromocriptine, dihydroergotamine, ergotamine, methylergometrine (methylergonovine), methysergide, pergolide)
mCPP
RU-24,969
Serotonin (5-HT)
Triptans (e.g., avitriptan, donitriptan, eletriptan, sumatriptan, zolmitriptan)
TFMPP
Tryptamines (e.g., 5-BT, 5-CT, 5-MT, DMT)
Vortioxetine

Antagonists: AR-A000002
Beta blockers (e.g., alprenolol, carteolol, isamoltane, oxprenolol, penbutolol, propranolol, tertatolol)
Elzasonan
Ergolines (e.g., metergoline)
GR-127935
Isamoltane
LY-393558
Metitepine (methiothepin)
SB-216641
SB-224289
SB-236057
Yohimbine

Unknown/unsorted: Ergolines (e.g., cabergoline, ergometrine (ergonovine), lisuride)
5-HT1D
Agonists: CP-122,288
CP-135807
CP-286601
Ergolines (e.g., bromocriptine, cabergoline, dihydroergotamine, ergotamine, LSD, methysergide)
GR-46611
L-694247
L-772405
mCPP
PNU-109291
PNU-142633
Serotonin (5-HT)
TGBA01AD
Triptans (e.g., almotriptan, avitriptan, donitriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan)
Tryptamines (e.g., 5-BT, 5-CT, 5-Et-DMT, 5-MT, 5-(nonyloxy)tryptamine, DMT)

Antagonists: Alniditan
BRL-15,572
Elzasonan
Ergolines (e.g., metergoline)
GR-127935
Ketanserin
LY-310762
LY-367642
LY-393558
LY-456219
LY-456220
Metitepine (methiothepin)
Mianserin
Ritanserin
Yohimbine
Ziprasidone

Unknown/unsorted: Acetryptine
Ergolines (e.g., lisuride, lysergol, pergolide)
5-HT1E
Agonists: BRL-54443
Ergolines (e.g., methysergide)
Serotonin (5-HT)
Triptans (e.g., eletriptan)
Tryptamines (e.g., tryptamine)

Antagonists: Metitepine (methiothepin)

Unknown/unsorted: Ergolines (e.g., ergometrine (ergonovine), lysergol, methylergometrine (methylergonovine)
5-HT1F
Agonists: BRL-54443
CP-122,288
Ergolines (e.g., bromocriptine, lysergol, methylergometrine (methylergonovine) methysergide)
Lasmiditan
LY-334370
Serotonin (5-HT)
Triptans (e.g., eletriptan, naratriptan, sumatriptan)
Tryptamines (e.g., 5-MT)

Antagonists: Metitepine (methiothepin)
Mianserin
5-HT25-HT2A
Agonists: 25H/NB series (e.g., 25I-NBF, 25I-NBMD, 25I-NBOH, 25I-NBOMe, 25B-NBOMe, 25C-NBOMe, 25TFM-NBOMe, 2CBCB-NBOMe, 25CN-NBOH, 2CBFly-NBOMe)
2Cs (e.g., 2C-B, 2C-E, 2C-I, 2C-T-2, 2C-T-7, 2C-T-21)
2C-B-FLY
2CB-Ind
5-Methoxytryptamines (5-MeO-DET, 5-MeO-DiPT, 5-MeO-DMT, 5-MeO-DPT, 5-MT)
α-Alkyltryptamines (e.g., 5-Cl-αMT, 5-Fl-αMT, 5-MeO-αET, 5-MeO-αMT, α-Me-5-HT, αET, αMT)
AL-34662
AL-37350A
Bromo-DragonFLY
Dimemebfe
DMBMPP
DOx (e.g., DOB, DOC, DOI, DOM)
Efavirenz
Ergolines (e.g., 1P-LSD, ALD-52, bromocriptine, cabergoline, ergine (LSA), ergometrine (ergonovine), ergotamine, lisuride, LA-SS-Az, LSB, LSD, LSD-Pip, LSH, LSP, methylergometrine (methylergonovine), pergolide)
Flumexadol
Jimscaline
Lorcaserin
MDxx (e.g., MDA (tenamfetamine), MDMA (midomafetamine), MDOH, MMDA)
O-4310
Oxaflozane
PHA-57378
PNU-22394
PNU-181731
RH-34
Phenethylamines (e.g., lophophine, mescaline)
Piperazines (e.g., BZP, quipazine, TFMPP)
Serotonin (5-HT)
TCB-2
TFMFly
Tryptamines (e.g., 5-BT, 5-CT, bufotenin, DET, DiPT, DMT, DPT, psilocin, psilocybin, tryptamine)

Antagonists: 5-I-R91150
5-MeO-NBpBrT
AC-90179
Adatanserin
Altanserin
Antihistamines (e.g., cyproheptadine, hydroxyzine, ketotifen, perlapine)
AMDA
Atypical antipsychotics (e.g., amperozide, aripiprazole, asenapine, blonanserin, brexpiprazole, carpipramine, clocapramine, clorotepine, clozapine, fluperlapine, gevotroline, iloperidone, lurasidone, melperone, mosapramine, ocaperidone, olanzapine, paliperidone, quetiapine, risperidone, sertindole, zicronapine, ziprasidone, zotepine)
Chlorprothixene
Cinanserin
CSP-2503
Deramciclane
Dotarizine
Eplivanserin
Ergolines (e.g., amesergide, LY-53857, LY-215,840, mesulergine, metergoline, methysergide, sergolexole)
Fananserin
Flibanserin
Glemanserin
Irindalone
Ketanserin
KML-010
Landipirdine
LY-393558
mCPP
Medifoxamine
Metitepine (methiothepin)
MIN-117 (WF-516)
Naftidrofuryl
Nantenine
Nelotanserin
Opiranserin (VVZ-149)
Pelanserin
Phenoxybenzamine
Pimavanserin
Pirenperone
Pizotifen
Pruvanserin
Rauwolscine
Ritanserin
Roluperidone
S-14671
Sarpogrelate
Serotonin antagonists and reuptake inhibitors (e.g., etoperidone, hydroxynefazodone, lubazodone, mepiprazole, nefazodone, triazoledione, trazodone)
SR-46349B
TGBA01AD
Teniloxazine
Temanogrel
Tetracyclic antidepressants (e.g., amoxapine, aptazapine, esmirtazapine, maprotiline, mianserin, mirtazapine)
Tricyclic antidepressants (e.g., amitriptyline)
Typical antipsychotics (e.g., chlorpromazine, fluphenazine, haloperidol, loxapine, perphenazine, pimozide, pipamperone, prochlorperazine, setoperone, spiperone, spiramide, thioridazine, thiothixene, trifluoperazine)
Volinanserin
Xylamidine
Yohimbine

Unknown/unsorted: Ergolines (e.g., dihydroergotamine, nicergoline)
5-HT2B
Agonists: 4-Methylaminorex
Aminorex
Amphetamines (e.g., chlorphentermine, cloforex, dexfenfluramine, fenfluramine, levofenfluramine, norfenfluramine)
BW-723C86
DOx (e.g., DOB, DOC, DOI, DOM)
Ergolines (e.g., cabergoline, dihydroergocryptine, dihydroergotamine, ergotamine, methylergometrine (methylergonovine), methysergide, pergolide)
Lorcaserin
MDxx (e.g., MDA (tenamfetamine), MDMA (midomafetamine), MDOH, MMDA)
Piperazines (e.g., TFMPP)
PNU-22394
Ro60-0175
Serotonin (5-HT)
Tryptamines (e.g., 5-BT, 5-CT, 5-MT, α-Me-5-HT, bufotenin, DET, DiPT, DMT, DPT, psilocin, psilocybin, tryptamine)

Antagonists: Agomelatine
Atypical antipsychotics (e.g., amisulpride, aripiprazole, asenapine, brexpiprazole, cariprazine, clozapine, N-desalkylquetiapine (norquetiapine), N-desmethylclozapine (norclozapine), olanzapine, pipamperone, quetiapine, risperidone, ziprasidone)
Cyproheptadine
EGIS-7625
Ergolines (e.g., amesergide, bromocriptine, lisuride, LY-53857, LY-272015, mesulergine)
Ketanserin
LY-393558
mCPP
Metadoxine
Metitepine (methiothepin)
Pirenperone
Pizotifen
Propranolol
PRX-08066
Rauwolscine
Ritanserin
RS-127445
Sarpogrelate
SB-200646
SB-204741
SB-206553
SB-215505
SB-221284
SB-228357
SDZ SER-082
Tegaserod
Tetracyclic antidepressants (e.g., amoxapine, mianserin, mirtazapine)
Trazodone
Typical antipsychotics (e.g., chlorpromazine)
TIK-301
Yohimbine

Unknown/unsorted: Ergolines (e.g., ergometrine (ergonovine))
5-HT2C
Agonists: 2Cs (e.g., 2C-B, 2C-E, 2C-I, 2C-T-2, 2C-T-7, 2C-T-21)
5-Methoxytryptamines (5-MeO-DET, 5-MeO-DiPT, 5-MeO-DMT, 5-MeO-DPT, 5-MT)
α-Alkyltryptamines (e.g., 5-Cl-αMT, 5-Fl-αMT, 5-MeO-αET, 5-MeO-αMT, α-Me-5-HT, αET, αMT)
A-372159
AL-38022A
Alstonine
CP-809101
Dimemebfe
DOx (e.g., DOB, DOC, DOI, DOM)
Ergolines (e.g., ALD-52, cabergoline, dihydroergotamine, ergine (LSA), ergotamine, lisuride, LA-SS-Az, LSB, LSD, LSD-Pip, LSH, LSP, pergolide)
Flumexadol
Lorcaserin
MDxx (e.g., MDA (tenamfetamine), MDMA (midomafetamine), MDOH, MMDA)
MK-212
ORG-12962
ORG-37684
Oxaflozane
PHA-57378
Phenethylamines (e.g., lophophine, mescaline)
Piperazines (e.g., aripiprazole, BZP, mCPP, quipazine, TFMPP)
PNU-22394
PNU-181731
Ro60-0175
Ro60-0213
Serotonin (5-HT)
Tryptamines (e.g., 5-BT, 5-CT, bufotenin, DET, DiPT, DMT, DPT, psilocin, psilocybin, tryptamine)
Vabicaserin
WAY-629
WAY-161503
YM-348

Antagonists: Adatanserin
Agomelatine
Atypical antipsychotics (e.g., asenapine, clorotepine, clozapine, fluperlapine, iloperidone, melperone, olanzapine, paliperidone, quetiapine, risperidone, sertindole, ziprasidone, zotepine)
Captodiame
CEPC
Cinanserin
Cyproheptadine
Deramciclane
Desmetramadol
Dotarizine
Eltoprazine
Ergolines (e.g., amesergide, bromocriptine, LY-53857, LY-215,840, mesulergine, metergoline, methysergide, sergolexole)
Etoperidone
Fluoxetine
FR-260010
Irindalone
Ketanserin
Ketotifen
Latrepirdine (dimebolin)
Medifoxamine
Metitepine (methiothepin)
Nefazodone
Pirenperone
Pizotifen
Propranolol
Ritanserin
RS-102221
S-14671
SB-200646
SB-206553
SB-221284
SB-228357
SB-242084
SB-243213
SDZ SER-082
Tedatioxetine
Tetracyclic antidepressants (e.g., amoxapine, aptazapine, esmirtazapine, maprotiline, mianserin, mirtazapine)
TIK-301
Tramadol
Trazodone
Tricyclic antidepressants (e.g., amitriptyline, nortriptyline)
Typical antipsychotics (e.g., chlorpromazine, loxapine, pimozide, pipamperone, thioridazine)
Xylamidine

Unknown/unsorted: Efavirenz
Ergolines (e.g., ergometrine (ergonovine), methylergometrine (methylergonovine))
5-HT3–75-HT3
Agonists: Alcohols (e.g., butanol, ethanol (alcohol), trichloroethanol)
m-CPBG
Phenylbiguanide
Piperazines (e.g., BZP, mCPP, quipazine)
RS-56812
Serotonin (5-HT)
SR-57227
SR-57227A
Tryptamines (e.g., 2-Me-5-HT, 5-CT, bufotenidine (5-HTQ))
Volatiles/gases (e.g., halothane, isoflurane, toluene, trichloroethane)
YM-31636

Antagonists: Alosetron
Anpirtoline
Arazasetron
AS-8112
Atypical antipsychotics (e.g., clozapine, olanzapine, quetiapine)
Azasetron
Batanopride
Bemesetron (MDL-72222)
Bupropion
Cilansetron
CSP-2503
Dazopride
Dolasetron
Galanolactone
Granisetron
Hydroxybupropion
ICS-205930
Lerisetron
Memantine
Ondansetron
Palonosetron
Ramosetron
Renzapride
Ricasetron
Tedatioxetine
Tetracyclic antidepressants (e.g., amoxapine, mianserin, mirtazapine)
Thujone
Tropanserin
Tropisetron
Typical antipsychotics (e.g., loxapine)
Volatiles/gases (e.g., nitrous oxide, sevoflurane, xenon)
Vortioxetine
Zacopride
Zatosetron

Unknown/unsorted: LY-53857
Piperazines (e.g., naphthylpiperazine)
5-HT4
Agonists: 5-MT
BIMU8
Capeserod
Cinitapride
Cisapride
CJ-033466
Dazopride
Metoclopramide
Minesapride
Mosapride
Prucalopride
PRX-03140
Renzapride
RS-67,333
RS-67,506
Serotonin (5-HT)
Tegaserod
Usmarapride
Velusetrag
Zacopride

Antagonists: GR-113808
GR-125487
L-Lysine
Piboserod
RS-39604
RS-67532
SB-203186
SB-204070
5-HT5A
Agonists: Ergolines (e.g., 2-Br-LSD (BOL-148), ergotamine, LSD)
Serotonin (5-HT)
Tryptamines (e.g., 5-CT)
Valerenic acid

Antagonists: Asenapine
Latrepirdine (dimebolin)
Metitepine (methiothepin)
Ritanserin
SB-699551
Unknown/unsorted: Ergolines (e.g., metergoline, methysergide)
Piperazines (e.g., naphthylpiperazine)
5-HT6
Agonists: Ergolines (e.g., dihydroergocryptine, dihydroergotamine, ergotamine, lisuride, LSD, mesulergine, metergoline, methysergide)
Hypidone
Serotonin (5-HT)
Tryptamines (e.g., 2-Me-5-HT, 5-BT, 5-CT, 5-MT, Bufotenin, E-6801, E-6837, EMD-386088, EMDT, LY-586713, N-Me-5-HT, ST-1936, tryptamine)
WAY-181187
WAY-208466

Antagonists: ABT-354
Atypical antipsychotics (e.g., aripiprazole, asenapine, clorotepine, clozapine, fluperlapine, iloperidone, olanzapine, tiospirone)
AVN-101
AVN-211
AVN-322
AVN-397
BGC20-760
BVT-5182
BVT-74316
Cerlapirdine
EGIS-12,233
GW-742457
Idalopirdine
Ketanserin
Landipirdine
Latrepirdine (dimebolin)
Masupirdine
Metitepine (methiothepin)
MS-245
PRX-07034
Ritanserin
Ro 04-6790
Ro 63-0563
SB-258585
SB-271046
SB-357134
SB-399885
SB-742457
Tetracyclic antidepressants (e.g., amoxapine, mianserin)
Tricyclic antidepressants (e.g., amitriptyline, clomipramine, doxepin, nortriptyline)
Typical antipsychotics (e.g., chlorpromazine, loxapine)

Unknown/unsorted: Ergolines (e.g., 2-Br-LSD (BOL-148), bromocriptine, lergotrile, pergolide)
Piperazines (e.g., naphthylpiperazine)
5-HT7
Agonists: 8-OH-DPAT
AS-19
Bifeprunox
E-55888
Ergolines (e.g., LSD)
LP-12
LP-44
LP-211
RU-24,969
Sarizotan
Serotonin (5-HT)
Triptans (e.g., frovatriptan)
Tryptamines (e.g., 5-CT, 5-MT, bufotenin, N-Me-5-HT)

Antagonists: Atypical antipsychotics (e.g., amisulpride, aripiprazole, asenapine, brexpiprazole, clorotepine, clozapine, fluperlapine, olanzapine, risperidone, sertindole, tiospirone, ziprasidone, zotepine)
Butaclamol
DR-4485
EGIS-12,233
Ergolines (e.g., 2-Br-LSD (BOL-148), amesergide, bromocriptine, cabergoline, dihydroergotamine, ergotamine, LY-53857, LY-215,840, mesulergine, metergoline, methysergide, sergolexole)
JNJ-18038683
Ketanserin
LY-215,840
Metitepine (methiothepin)
Ritanserin
SB-258719
SB-258741
SB-269970
SB-656104
SB-656104A
SB-691673
SLV-313
SLV-314
Spiperone
SSR-181507
Tetracyclic antidepressants (e.g., amoxapine, maprotiline, mianserin, mirtazapine)
Tricyclic antidepressants (e.g., amitriptyline, clomipramine, imipramine)
Typical antipsychotics (e.g., acetophenazine, chlorpromazine, chlorprothixene, fluphenazine, loxapine, pimozide)
Vortioxetine

Unknown/unsorted: Ergolines (e.g., lisuride, pergolide)
Piperazines (e.g., naphthylpiperazine)

See also: Receptor/signaling modulators
Adrenergics
Dopaminergics
Melatonergics
Monoamine reuptake inhibitors and releasing agents
Monoamine metabolism modulators
Monoamine neurotoxins

vtePhenethylaminesPhenethylamines
Psychedelics: 25B-NBOMe
25C-NBOMe
25D-NBOMe
25I-NBOMe
25N-NBOMe
2C-B
2C-B-AN
2C-Bn
2C-Bu
2C-C
2C-CN
2C-CP
2C-D
2C-E
2C-EF
2C-F
2C-G
2C-G-1
2C-G-2
2C-G-3
2C-G-4
2C-G-5
2C-G-6
2C-G-N
2C-H
2C-I
2C-iP
2C-N
2C-NH2
2C-O
2C-O-4
2C-P
2C-Ph
2C-SE
2C-T
2C-T-2
2C-T-3
2C-T-4
2C-T-5
2C-T-6
2C-T-7
2C-T-8
2C-T-9
2C-T-10
2C-T-11
2C-T-12
2C-T-13
2C-T-14
2C-T-15
2C-T-16
2C-T-17
2C-T-18
2C-T-19
2C-T-20
2C-T-21
2C-T-22
2C-T-22.5
2C-T-23
2C-T-24
2C-T-25
2C-T-27
2C-T-28
2C-T-30
2C-T-31
2C-T-32
2C-T-33
2C-TFE
2C-TFM
2C-YN
2C-V
Allylescaline
DESOXY
Escaline
Isoproscaline
Jimscaline
Macromerine
MEPEA
Mescaline
Metaescaline
Methallylescaline
Proscaline
Psi-2C-T-4
TCB-2
Stimulants: Phenylethanolamine

Hordenine
Phenethylamine
Phenpromethamine
α-Methylphenethylamine (amphetamine)
β-Methylphenethylamine
m-Methylphenethylamine
N-Methylphenethylamine
o-Methylphenethylamine
p-Methylphenethylamine
Methylphenidate
Entactogens: Lophophine
MDPEA
MDMPEAOthers: BOH
DMPEA
Amphetamines
Psychedelics: 3C-AL
3C-BZ
3C-E
3C-MAL
3C-P
Aleph
Beatrice
Bromo-DragonFLY
D-Deprenyl
DMA
DMCPA
DMMDA
DOB
DOC
DOEF
DOET
DOI
DOM
DON
DOPR
DOTFM
Ganesha
MMDA
MMDA-2
Psi-DOM
TMA
TeMA
ZDCM-04Stimulants: 2-FA
2-FMA
3-FA
3-FMA
Acridorex
Alfetamine
Amfecloral
Amfepentorex
Amphetamine (Dextroamphetamine, Levoamphetamine)
Amphetaminil
Benfluorex
Benzphetamine
Cathine
Clobenzorex
Dimethylamphetamine
Ephedrine
Etilamfetamine
Fencamfamin
Fencamine
Fenethylline
Fenfluramine (Dexfenfluramine, Levofenfluramine)
Fenproporex
Flucetorex
Fludorex
Formetorex
Furfenorex
Gepefrine
4-Hydroxyamphetamine
Iofetamine
Isopropylamphetamine
Lefetamine
Lisdexamfetamine
Mefenorex
Metaraminol
Methamphetamine (Dextromethamphetamine, Levomethamphetamine)
Methoxyphenamine
MMA
Morforex
Norfenfluramine
L-Norpseudoephedrine
N,alpha-Diethylphenylethylamine
Oxifentorex
Oxilofrine
Ortetamine
PBA
PCA
PFA
PFMA
PIA
PMA
PMEA
PMMA
Phenylpropanolamine
Pholedrine
Prenylamine
Propylamphetamine
Pseudoephedrine
Sibutramine
Tiflorex
Tranylcypromine
Xylopropamine
ZylofuramineEntactogens: 4-FA
4-FMA
4-MA
4-MMA
4-MTA
5-APB
5-APDB
5-EAPB
5-IT
5-MAPB
5-MAPDB
6-APB
6-APDB
6-Chloro-MDMA
6-EAPB
6-IT
6-MAPB
6-MAPDB
EDA
IAP
2,3-MDA
3,4-MDA (tenamfetamine)
MDEA
MDHMA
MDMA (midomafetamine)
MDOH
Methamnetamine
MMDMA
Naphthylaminopropane
TAPOthers: 3,4-DCA
Amiflamine
DiFMDA
Selegiline (also D-Deprenyl)
Phentermines
Stimulants: Chlorphentermine
Cloforex
Clortermine
Etolorex
Mephentermine
Pentorex
PhentermineEntactogens: MDPH
MDMPHOthers: Cericlamine
Cathinones
Stimulants: 3-FMC
4-MC
4-BMC
4-CMC
4-EMC
4-FMC
4-MEC
4-MeMABP
4-MPD
Amfepramone
Benzedrone
Brephedrone
Buphedrone
Bupropion
Cathinone
Dimethylcathinone
Ethcathinone
Eutylone
Hydroxybupropion
Methcathinone
Methedrone
NEB
N-Ethylhexedrone
N-Ethylpentedrone
Pentedrone
Pentylone
RadafaxineEntactogens: 3,4-DMMC
3-MMC
Butylone
Ethylone
Methylone
Methylenedioxycathinone
Mephedrone
Phenylisobutylamines
Entactogens: 4-CAB
4-MAB
Ariadne
BDB
Butylone
EBDB
Eutylone
MBDBStimulants: Phenylisobutylamine
Phenylalkylpyrrolidines
Stimulants: α-PBP
α-PHP
α-PPP
α-PVP
MDPBP
MDPPP
MDPV
4-MePBP
4-MePHP
4-MePPP
MOPPP
MOPVP
MPBP
MPHP
MPPP
Naphyrone
PEP
Prolintane
Pyrovalerone
Catecholamines(and close relatives)
6-FNE
6-OHDA
a-Me-DA
a-Me-TRA
Adrenochrome
Ciladopa
D-DOPA (Dextrodopa)
Dimetofrine
Dopamine
Epinephrine
Epinine
Etilefrine
Ethylnorepinephrine
Fenclonine
Ibopamine
Isoprenaline
Isoetarine
L-DOPA (Levodopa)
L-DOPS (Droxidopa)
L-Phenylalanine
L-Tyrosine
m-Tyramine
Metanephrine
Metaraminol
Metaterol
Metirosine
Methyldopa
N,N-Dimethyldopamine
Nordefrin (Levonordefrin)
Norepinephrine
Norfenefrine (m-Octopamine)
Normetanephrine
Orciprenaline
p-Octopamine
p-Tyramine
Phenylephrine
Synephrine
Miscellaneous
AL-LAD
Amidephrine
Arbutamine
Cafedrine
Denopamine
Desvenlafaxine
Diphenidine
Dizocilpine
Dobutamine
Dopexamine
Ephenidine
Etafedrine
ETH-LAD
Famprofazone
Fluorolintane
Hexapradol
IP-LAD
Lysergic acid amide
Lysergic acid 2-butyl amide
Lysergic acid 2,4-dimethylazetidide
Lysergic acid diethylamide
Methoxamine
Methoxphenidine
MT-45
PARGY-LAD
Phenibut
PRO-LAD
Pronethalol
Salbutamol (Levosalbutamol)
Solriamfetol
Theodrenaline
Thiamphenicol
UWA-101
Venlafaxine

vteGlaxoSmithKlineSubsidiaries
GlaxoSmithKline Pakistan
GlaxoSmithKline Pharmaceuticals Ltd
Stiefel Laboratories
Tesaro
ViiV Healthcare (85%)
Predecessors,acquisitions
Allen & Hanburys
Beecham Group
Block Drug
Burroughs Wellcome
Glaxo
Glaxo Wellcome
Human Genome Sciences
Recherche et Industrie Thérapeutiques
Reliant Pharmaceuticals
S. E. Massengill Company
SmithKline Beecham
Smith, Kline & French
ProductsCurrentPharma
Advair
Alli
Augmentin
Avandia
Beconase
Boniva
Flixonase
Hycamtin
Lamictal
Paxil/Seroxat
Serlipet
Tagamet
Ventolin
Wellbutrin/Zyban
Zantac … more
Vaccines
Hepatyrix
Pandemrix
Shingrix
Twinrix
Other
Aquafresh
Centrum
Horlicks
Nicoderm
Nicorette
NiQuitin
Sensodyne
Tums … more
Former
BC Powder
Geritol
Goody's Powder
Lucozade
Ribena
PeopleBoard of Directors
Philip Hampton
Emma Walmsley
Simon Dingemans
Roy M. Anderson
Manvinder Banga 
Patrick Vallance
Vivienne Cox
Lynn Elsenhans
Jesse Goodman
Judy Lewent
Urs Rohner
Laurie Glimcher
Other
Thomas Beecham
Silas M. Burroughs
Mahlon Kline
John K. Smith
Henry Wellcome
Andrew Witty
Chris Gent
Litigation
Canada v. GlaxoSmithKline Inc.
Christopher v. SmithKline Beecham Corp.
GlaxoSmithKline Services Unlimited v Commission
United States v. Glaxo Group Ltd.
United States v. GlaxoSmithKline
Other
Drug Industry Documents Archive
GlaxoSmithKline Prize
Side Effects
Study 329

 Category

.mw-parser-output .portal-bar{font-size:88%;font-weight:bold;display:flex;justify-content:center;align-items:baseline}.mw-parser-output .portal-bar-bordered{padding:0 2em;background-color:#fdfdfd;border:1px solid #a2a9b1;clear:both;margin:1em auto 0}.mw-parser-output .portal-bar-unbordered{padding:0 1.7em;margin-left:0}.mw-parser-output .portal-bar-header{margin:0 1em 0 0.5em;padding:0.2em 0;flex:0 0 auto;min-height:24px;line-height:22px}.mw-parser-output .portal-bar-content{display:flex;flex-flow:row wrap;align-items:baseline;flex:0 1 auto;padding:0.15em 0;column-gap:1em}.mw-parser-output .portal-bar-item{display:flex;align-items:baseline;margin:0.15em 0;min-height:24px;text-align:left}.mw-parser-output .portal-bar-logo{width:22px;line-height:22px;margin:0 0.2em;text-align:right}.mw-parser-output .portal-bar-link{margin:0 0.2em;text-align:left}@media screen and (max-width:768px){.mw-parser-output .portal-bar{font-size:88%;font-weight:bold;display:flex;flex-flow:column wrap}.mw-parser-output .portal-bar-header{text-align:center;flex:0;padding-left:0.5em;margin:0 auto}.mw-parser-output .portal-bar-content{display:flex;flex-flow:row wrap;align-items:baseline;flex:0;margin:0 auto;column-gap:1em;border-top:1px solid #a2a9b1}}.mw-parser-output .navbox+link+.portal-bar-bordered{margin-top:-1px}.mw-parser-output .navbox+style+.portal-bar-bordered{margin-top:-1px}.mw-parser-output .portal-bar+.navbox-styles+.navbox{margin-top:-1px}Portal:Medicine





